

Human Vaccines & Immunotherapeutics awards Top Reviewer of the Year

Ronald Ellis & Adam Weiss

To cite this article: Ronald Ellis & Adam Weiss (2017) *Human Vaccines & Immunotherapeutics* awards Top Reviewer of the Year, *Human Vaccines & Immunotherapeutics*, 13:1, 2-8, DOI: [10.1080/21645515.2017.1278979](https://doi.org/10.1080/21645515.2017.1278979)

To link to this article: <https://doi.org/10.1080/21645515.2017.1278979>



Published online: 26 Jan 2017.



Submit your article to this journal [↗](#)



Article views: 627



View Crossmark data [↗](#)

EDITOR'S CORNER

Human Vaccines & Immunotherapeutics awards Top Reviewer of the Year

Ronald Ellis^a and Adam Weiss^b


^aFutuRx, Ltd., Ness Ziona, Israel; ^bTaylor & Francis Group, Prague, Czech Republic

Human Vaccines & Immunotherapeutics (HV&I) has concluded its 12th year of publication. We realize that maintaining the high quality of our journal with a rapid turnaround of articles from submission to publication would be impossible without the dedicated and skilled work of hundreds of Reviewers and Editors.

We would like to express our gratitude to all our Reviewers for their commitment, hard work and time. All Reviewers of 2016 are listed below.

In particular, we are pleased on behalf of the *HV&I* Editorial team and the Taylor & Francis Group to recognize and thank **Dr. Rebecca Perkins as the Top Reviewer of 2016**. Dr. Perkins is Associate Professor of Obstetrics and Gynecology at Boston University School of Medicine and a practicing physician at Boston Medical Center. Her main interest is in prevention of cervical and other HPV-related cancers through vaccination with the focus on interventions to increase HPV vaccination rates. She has published >50 articles in the field. Dr. Perkins was a Guest Editor for the *HV&I* Special Issue on HPV vaccines (Issue 12–6, June 2016) and is Associate Editor of the journal.

Previous awardees were Drs. Xuan-Yi Wang (Fudan University, Shanghai, China), Simonetta Viviani (Independent Advisor for Vaccines, Epidemiology & Public Health, Siena Italy), Brian Greenwood (London School of Hygiene and Tropical Medicine, UK), Brian Ward (McGill University, Montreal, Canada), James Tartaglia (Sanofi-Pasteur, Toronto, Canada), Joel Bozue (USAMRIID, Fort Detrick, MD, USA), Mark Kane (Consultant, Seattle, WA, USA), Arístides Aguilar Betancourt (Centre for Genetic Engineering & Biotechnology, Havana, Cuba), John Schiller (National Cancer Institute, Bethesda, MD, USA) and Mark Newman (consultant, Smyrna, Georgia, USA).



Rebecca B. Perkins (Photo by Massachusetts Medical Society)

Syed Abbas
Institute of Development Studies

Ahmed Abdul Mateen
*Novartis Pharmaceuticals
Canada Inc*

Ajibola Abioye
Brown University

Salah Al-Awaidy
Oman Ministry of Health

Igor Almeida
The University of Texas at El Paso

Louis Altamura
*United States Army Medical
Research Institute of Infectious
Diseases*

Robert Amato
University of Texas Medical School

Christopher Ambrose
MedImmune, LLC

Daniela Amicizia
University of Genoa

Annaliesa Anderson
Pfizer

María del Mar Andreu
MSSSI

Juana Angel
Pontificia Universidad Javeriana

Paulo Antas
IOC/Fiocruz

Silke Appel
University of Bergen

George Armah
University of Ghana

Stephen Aston
Liverpool School of Tropic Medicine

Reda Awali
Wayne State University

Sita Awasthi
University of Pennsylvania

Eduardo Azziz-Baumgartner
*Centers for Disease Control and
Prevention*

Ashley Banyard
Animal and Plant Health Agency

Daniel Bausch
*Tulane University Health Science
Center*

Sandra Bean
Oregon State University

Rodolfo Bégué
*Louisiana University Health
Sciences Center*

Ahmed Bellah
*World Health Organisation,
Switzerland*

Bernd Benninghoff
GSK Vaccines

Shalom Ben-Shimol
*Ben-Gurion University of the Negev
and Soroka University Medical
Center*

Julie Bettinger
*Vaccine Evaluation Center, BC
Children's Hospital, University of
British Columbia*

Omesh Bharti
*State Institute of Health & Family
Welfare*

Dr. Sujit Bhattacharya
*National Institute of Cholera and
Enteric Disease*

Prakash Bhuyan
Inovio

Susan Bock
Utah State University

- Fabiola Bof de Andrade**
Oswaldo Cruz Foundation - Rene Rachou Research Institute
- Aurelio Bonavia**
AERAS
- Kobporn Boonnak**
Mahidol University
- Wegene Borena**
Medical University of Innsbruck
- Jason Botten**
University of Vermont College of Medicine
- Alain Bouckennooghe**
Sanofi Pasteur
- Michael Bowen**
CDC
- Andrzej Bozek**
Medical University of Silesia
- Joel Bozue**
USAMRIID Bacteriology
- Karine Breckpot**
Vrije Universiteit Brussel
- Robert Bright**
Texas Tech University Health Science Center
- Rosemary Burnett**
Sefako Makgatho Health Sciences University
- Alison Buttenheim**
University of Pennsylvania School of Nursing
- David Callender**
Univeristy of Massachusetts Amherst
- William Calo**
University of North Carolina, Gillings School of Global Public Health
- Anna Calvert**
St George's, University of London
- Daniela Cardozo**
UNICAMP
- Andrew Carson-Stevens**
Cardiff University
- Herve Caspard**
MedImmune
- Antonio Cassone**
Parasitic and Immuno-mediated Diseases Istituto Superiore di Sanità
- Manuel Garcia Cenoz**
Public Health Institute of Navarra
- Stuart Clarke**
University of Southampton, School of Medicine
- Nakia Clemmons**
CDCP
- Richard Connolly**
Oncosec Medical Corp
- Ken Coppieters**
Novo Nordisk Inc.
- Paul Corben**
Mid North Coast Local Health District
- Ana Coroadinha**
Universidade Nova de Lisboa
- Paul Coussens**
Michigan State University
- Anne Cowan**
University of Michigan
- Josephine Cox**
IAVI
- C. Buddy Creech**
Vanderbilt University School of Medicine and the Monroe Carell, Jr. Children's Hospital at Vanderbilt
- Cathy Critchlow**
Amgen
- Tim Crocker-Buque**
London School of Hygiene of Tropical Medicine
- Nicolas Cuburu**
National Cancer Institute
- Fuqiang Cui**
Chinese Center for Disease Control and Prevention
- Zhengrong Cui**
University of Texas at Austin
- Aaron Curns**
Centers for Disease Control and Prevention
- Ron Dagan**
Pediatric Infectious Disease Unit, Soroka University Medical Center Faculty of Health Sciences, Ben-Gurion University of the Negev
- Paolo D'Ancona**
Istituto Superiore Di Sanita
- Adil Daud**
University of California at San Francisco
- Robert Daum**
University of Chicago
- Irja Davidken**
National Institute for Health and Welfare
- Ghassan Dbaibo**
American University of Beirut Medical Center
- Serge De Valliere**
University Hospital of Lausanne
- Chiara De Waure**
Università Cattolica del Sacro Cuore
- Shelley Deeks**
Ontario Agency for Health Protection and Promotion
- Xuan Deng**
Zhejiang CDC
- Gaurav Deshpande**
HealthCore Inc
- Ulrich Desselberger**
Department of Medicine, Addenbrooke's Hospital
- Aditi Dey**
National Centre for Immunisation Research & Surveillance
- Mandeep Dhingra**
Sanofi Pasteur
- Gabriella Di Giuseppe**
University of Naples
- Javier Diez-Domingo**
Centro Superior de Investigacion en Salud Publica (CSISP), Valencia, Spain
- Dimiter Dimitrov**
CCRNP, CCR, NCI-Frederick, NIH
- Ener Dinleyici**
Eskisehir Osmangazi University Faculty of Medicine
- Maurizio Divizia**
University of Rome Tor Vergata
- Guillermo Docena**
LISIN, Facultad de Ciencias Exactas, Universidad Nacional de La Plata
- Mark Doherty**
GSK
- Ángela Dominguez**
Universitat de Barcelona
- John Donnelly**
Global Healing
- Ryan Donnelly**
Queens University Belfast
- Philip Dormitzer**
Pfizer Vaccines
- Lanying Du**
Lindsay F. Kimball Research Institute, New York Blood Center
- Donald Dudley**
University of Virginia
- Andrew Dunning**
- Paolo Durando**
University of Genoa
- Maren Eggers**
Labor Enders
- Laurie Elam-Evans**
CDC
- David Elliman**
Great Ormond Street Hospital
- Ronald Ellis**
FutuRx Ltd.
- Olivier Epaulard**
University Hospital
- Jose Esparza**
University of Maryland
- Susanna Esposito**
Department of Pathophysiology and Transplantation, University of Milan
- Bart Faber**
BPRC
- Kamal Fahmy**
Vaccine Preventable Diseases and Immunization, Department of Communicable Disease Prevention and Control, WHO Regional Office for the Eastern Mediterranean
- Xiaoyong Fan**
Shanghai Public Health Clinical Center, Fudan University
- Gaetano Fara**
University of Rome
- M.M.A. Faridi**
University College of Medical Sciences
- David Fedson**
retired
- Kristen Feemster**
Children's Hospital of Philadelphia
- Tania Felizardo**
National Cancer Institute
- Catterina Ferreccio**
Facultad Medicina Pontificia Universidad Catolica de Chile, Santiago, Chile
- Robert Fisher**
FDA - HHS

Mario Alberto Flores-Valdez
CIATEJ, A.C.

Terence R. Flotte
University of Massachusetts Medical
School Suite S1-340, 55 Lake Avenue
North, Worcester, Massachusetts
01655, USA.

Nicolas Folschweiller
GSK Vaccines

Toni Fooks
Animal Health and Veterinary Labo-
ratories Agency (AHLAV, Wey-
bridge), New Haw Addlestone, UK,
and Department of Clinical Infec-
tion, Microbiology and Immunology,
Institute of Infection and Global Hea

Ivo Foppa
CDCP

Maria Foti
Department of Biotechnology and
Bioscience, University of Milano-
Bicocca

Genevieve Fouda
Duke University

Christopher Fox
IDRI

Silvia Franceschi
IARC

Elisabetta Franco
University of Rome Tor Vergata

Chuanxi Fu
Guangzhou Center for Disease Con-
trol and Prevention

Giovanni Gabutti
University of Ferrara, Italy

Hui Gan
Olivia Newton-John Cancer
Research Institute

Alberto García-Basteiro
Barcelona Institute for Global
Health

José García-Sicilia
University Children Hospital La Paz

Nathalie Garçon
Bioaster

Lisa Gargano
Emory University

Lindsey Garver-Baldwin
Walter Reed Army Institute of
Research

Luca Gattinoni
National Cancer Institute

Julianne Gee
Centers for Disease Control and
Prevention

Yvonne Genzel
Max Planck Institute

Eddie Gibson
Wickenstones Ltd

Angel Gil de Miguel
Universidad Rey Juan Carlos

Nicolas Gilbert
Public Health Agency of Canada

Vladimir Gilca
Quebec Public Health Institute,
Laval University, Laval University
Research Hospital Center

Ann Ginsberg
Aeras

Rosa Gofin
Hebrew University

Gyanendra Gongal
World Health Organization

Gregory Gormowski
National Institute of Allergy and
Infectious Diseases

Andrew Gorringe
Health Protection Agency

John Grabenstein
Merck

Amy Greer
University of Guelph

Petros Grivas
Cleveland Clinic

Gideon Gross
MIGAL-Galilee Research Institute

Maria Rosaria Gualano
University of Turin

Danielle Guarracino
The College of New Jersey

Duane Gubler
Duke-NUS Graduate School

Sevtap Guney
Akdeniz University Faculty of
Medicine

Carlos Guzman
Helmholtz Centre for Infection
Research

Inaya Hajj Hussein
Oakland University William Beau-
mont School of Medicine

Beth Halperin
Dalhousie University

Willem Hanekom
Bill and Melinda Gates Foundation

Michael Hanna Jr
Vaccinogen Inc.

**Ashwathnarayana
Hanumanthaiah**
Kempegowda Institute of Medical
Sciences

Shunji Hasegawa
Yamaguchi University Graduate
School of Medicine

Steven Hawken
Ottawa Hospital Research Institute

JS He
College of Life Sciences & Bioengi-
neering, Beijing Jiaotong University

Nagendra Hegde
Ella Foundation

Robert Holt
BC Genomics Science Center

Yoshi Horiuchi
National Institute of Infectious
Diseases

Johannes Horn
Helmholtz Centre for Infection
research

Jue Hou
Singapore-MIT Alliance Technology
(SMART)

Guy Houillon
Sanofi Pasteur

Jason Howard
Johns Hopkins University

Daniela Hozbor
Laboratorio VacSal. Instituto de Bio-
tecnología y Biología Molecular
(IBBM). Facultad de Ciencias Exac-
tas. Universidad Nacional de La
Plata. CCT-CONICET La Plata.
Calles 50 y 115. 1900.

Zhongyu Hu
National Institutes for Food and
Drug Control

Allison Chamberlain
Emory University

Venkateswarlu Chamcha
Emory University

Harrell Chesson
Centers for Disease Control and
Prevention

Ayman Chit
Sanofi Pasteur

Kow-Tong Chen
Department of Public Health,
College of Medicine

Robert Chen
Centers for Disease Control and
Prevention

Ze Chen
Shanghai Institute of Biological
Products, Shanghai, China

Salvatore Chirumbolo
University of Verona

Chong Chong
SSM Services

Giancarlo Icardi
University of Genoa

Maria Yuri Ichihara
Campo Universitário do Canela

Anna Iorio
University of Perugia

Irina Isakova-Sivak
Institute of Experimental Medicine

Chunlai Jiang
National Engineering Laboratory of
AIDS Vaccine

Hui Jin
School of Public Health, Southeast
University

Jin Jin
Zhejiang University

Nicholas Johnson
Veterinary Laboratories Agency

Ana Paula Junqueira-Kipnis
Laboratório de Imunopatologia das
Doenças Infecciosas, Instituto de
Patologia Tropical e Saúde Pública,
Universidade Federal de Goiás,
Goiânia, Goiás

Aras Kadioglu
University of Liverpool

Pawel Kalinski
University of Pittsburgh

Linda Kaljee
Henry Ford Health System

Mark Kane
Consultant

Sang-Moo Kang
Georgia State University

Emilie Karafillakis
London School of Hygiene and Trop-
ical Medicine

Om P. Katare
Division of Pharmaceuticals, Univer-
sity Institute of Pharmaceutical
Sciences UGC-Centre of Advanced
Study Panjab University

- Helena Kayhty**
National Institute for Health and Welfare
- Kylene Kehn-Hall**
George Mason University
- Woo Joo Kim**
Korea University College of Medicine
- Efrat Kochba**
NanoPass Technologies
- Sofia Kourkounti**
A Sygros Hospital
- Michael Kowarik**
LimmaTech Biologics
- Florian Krammer**
Icahn School of Medicine at Mount Sinai
- Pavla Krizova**
National Institute of Public Health (NIPH), Prague, Czech Republic
- Andrew Kroger**
Centers for Disease Control and Prevention
- Joanna Krzowska-Firyck**
Medical University of Lublin
- Jeremy Kudrna**
University of South Florida
- Nitesh Kunda**
University of New Mexico
- Michael Kundi**
Center for Public Health, Medical University of Vienna, Vienna, Austria. Tel: +43-1-4277-64726. Fax: +43-1-4277-9647.
- Asaomi Kuwae**
Kitasato University
- Yok-Lam Kwong**
Queen Mary Hospital
- Giuseppe La Torre**
Sapienza University of Rome
- Diego Laderach**
Universidad de Buenos Aires
- Ming-Wei Lai**
Chang Gung Memorial Hospital
- Terence Lao**
The Chinese University of Hong Kong
- Dagna Laufer**
International AIDS Vaccine Initiative
- Amy Leader**
Thomas Jefferson University
- Ting Fan Leung**
The Chinese University of Hong Kong
- Yotam Levin**
NanoPass Technologies
- Yinon Y. Levy**
Israel Institute for Biological Research
- Lijin Li**
Washington University School of Medicine
- Rongcheng Li**
GuangXi Center for Disease Prevention and Control
- Wei Li**
National Institutes of Health
- Xinlou Li**
Institute of Microbiology and Epidemiology in Beijing
- Xuguang (Sean) Li**
Health Canada & University of Ottawa
- Yapin Li**
Center for Disease Prevention and Control of Beijing Military Region
- Zhang Li**
Shandong Center for Disease Control and Prevention & Preventive Medical Institute of Shandong University & Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention
- Zhenglun Liang**
National Institutes for Food and Drug Control
- Kue Peng Lim**
Cancer Research Initiatives Foundation
- Megan Lindley**
Centers for Disease Control & Prevention
- Feng Liu**
Centers for Disease Control and Prevention
- Hui Liu**
Yubei Center for Disease Control and Prevention
- Man-Qing Liu**
Wuhan Centers for Disease Prevention and Control
- Pei Liu**
Southeast University
- Xiaowei Liu**
Arizona State University
- Xueen Liu**
Peking University Health Science Center
- Xu-Ping Liu**
East China University of Science and Technology
- Alvaro Lladser**
Fundación Ciencia & Vida
- Cheryl Lobo**
New York Blood Center
- Denis Logunov**
"Federal Research Centre of Epidemiology and Microbiology named Honorary Academician N. F. Gamaleya" of Ministry of Health of Russian Federation
- Vincent Lombardi**
Stallergenes
- Pier-Luigi Lopalco**
ECDC
- Shan Lu**
University of Massachusetts Medical School
- Pauline MacDonald**
National Health Service
- Donna MacDougall**
St. Francis Xavier University
- Denis Macina**
Sanofi Pasteur
- Aba Mahamat**
Cayenne General Hospital
- Tiejun Mai**
China Meitan General Hospital
- Claudius Malerczyk**
GSK Vaccines
- Cinzia Marano**
GSK Vaccines
- I.S. Marcipar**
Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Argentina
- Federico Marchetti**
GlaxoSmithKline Vaccines,
- Domenico Martinelli**
University of Foggia
- Paul Matejtschuk**
NIBSC
- Bonnie Mathieson**
US NIH
- E. McIntosh**
Imperial College
- John McLaughlin**
- Doug McNeel**
University of Wisconsin
- Merit Melin**
National Institute for Health and Welfare
- Hakan Mellstedt**
Karolinska University Hospital
- Claude Meric**
CHUV
- Jussi Mertsola**
Turku University Hospital
- Francois Meslin**
WHO (retired)
- Claudius Meyer**
University Hospital Mainz
- Darren Miller**
Adelaide University
- Philip Minor**
National Inst of Biol Standards & Controls
- Ian Mitchell**
University of Calgary
- Yaffa Mizrahi-Nebenzahl**
Soroka University Medical Center
- Kayvon Modjarrad**
Walter Red Army Institute for Research
- Leonard Moise**
EpiVax Inc.; Institute for Immunology and Informatics University of Rhode Island
- Garry Morefield**
VaxForm LLC
- Nikki Moreland**
University of Auckland
- Mitsuru Mori**
Sapporo Medical University School of Medicine
- Pedro Moro**
Centers for Disease Control and Prevention
- John Morris**
University of Cincinnati
- Trudy Morrison**
University of Massachusetts Medical School
- Alireza Mosavi Jarrahi**
School of Public Health, Shahid Beheshti University of Medical Sciences

- Khitam Muhsen**
Tel Aviv University
- Eszter Nagy**
Arsanis Biosciences
- Raffael Nachbagauer**
Mount Sinai School of Medicine
- Kei Nakashima**
Kameda Medical Center
- Keiko Nakata**
Osaka City University Graduate School of Medicine
- Ho Namkoong**
Keio University School of Medicine
- Aarthi Narayanan**
George Mason University
- Sonali Nashine**
University of California Irvine
- Mark Newman**
Consultant
- Christian Nixon**
Center for International Health Research/Alpert Medical School of Brown University
- Terry Nolan**
University of Melbourne
- Andrew Norman**
University of Cincinnati
- Glen Nowak**
University of Georgia
- Brendan Nyhan**
Dartmouth College
- Olumuyiwa Odusanya**
Lagos State University College of Medicine
- Tabatha Offutt-Powell**
Delaware Health and Social Services
- Olga Ochoa-Gondar**
Institut Català de la Salut
- Egbert Oosterwijk**
University Medical Center St Radboud
- Roberta Opri**
University of Verona
- Walter Orenstein**
Emory University
- Frank Orson**
Baylor College of Medicine
- Miguel O'Ryan**
University of Chile
- S. Owens**
University of Arkansas for Medical Sciences
- Yasemin Ozsurekci**
Hacettepe University Medical Faculty
- Orestis Panagiotou**
Brown University
- Vassiliki Papaevangelou**
National Kapodistrian University of Athens
- Elena Pariani**
University of Milan
- Janak Patel**
University of Texas Medical Branch
- James Paton**
University of Adelaide
- Jean Patterson**
Texas BioMedical
- Maria Pavia**
University of Catanzaro "Magna Græcia"
- Daniel Payne**
Centers for Disease Control and Prevention
- Silvia Pérez-Vilar**
FISABIO-Public Health
- Rebecca Perkins**
Boston University
- Michael Pichichero**
Rochester General Hospital Research Institute
- Claudia Pileggi**
University of Catanzaro "Magna Græcia"
- Robert Pless**
Public Health Agency of Canada
- Vitali Pool**
Sanofi Pasteur USA
- Jan Poolman**
Crucell
- Alexandra Porras Ramirez**
National University of Colombia
- Koen Pouwels**
University of Groningen
- Marco Pravetoni**
University of Minnesota
- D. Rebecca Prevots**
National Institute of Allergy and Infectious Diseases
- Firdausi Qadri**
International Center for Diarrheal Disease Research
- Cheng-Feng Qin**
Beijing Institute of Microbiology and Epidemiology
- Jiantai Qiu**
Chang Gung Memorial Hospital
- Raquel Qualls-Hampton**
Tennessee Department of Health
- Beatriz Quiambao**
Research Institute for Tropical Medicine
- Birgitte Rahbek Kornum**
Molecular Sleep Laboratory, Department of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark
- Jasna Rakonjac**
Massey University
- Ramakrishna Ramakrishna Vankayalapati**
U.Tyler
- Mario Ramirez**
Instituto de Microbiologia
- Sameer Rao**
Wockhardt Ltd
- Poonam Rath**
Stanford University
- Sarah Reagan-Steiner**
Centers for Disease Control and Prevention
- Jingjing Ren**
the First Affiliated Hospital, School of Medicine, Zhejiang University
- Pen Reyes**
University of New South Wales
- Giovanni Rezza**
Istituto Superiore di Sanità
- Thomas Richie**
Sanaria Inc
- Jürgen Rissland**
Universitätsklinikum des Saarlandes
- Barbara Romanowski**
University of Alberta
- Marc Rondy**
EpiConcept
- Alba María Roperó-Álvarez**
Pan American Health Organization
- Cecilia Roteli-Martins**
Leonor Mendes de Barros Hospital
- David Sack**
Johns Hopkins University
- Issaka Sagara**
University of Bamako
- Tejram Sahu**
Johns Hopkins University Bloomberg School of Public Health
- Akihiko Saitoh**
Niigata University Graduate School of Medical and Dental Sciences
- Naseem Salahuddin**
Liaquat Hospital
- Stefania Salmaso**
retired from ISS-Rome, Italy
- Prakash Sambhara**
Centers for Disease Control and Prevention
- Juan Carlos Sanz Moreno**
Laboratorio Regional de Salud Pública, Comunidad de Madrid
- Niranjan Sardesai**
Inovio Pharmaceuticals, Inc.
- Pablo Sarobe**
University of Navarra
- Andreas Sauerbrei**
University of Jena
- Rosella Saulle**
"Sapienza" University of Rome
- Natalia Savelyeva**
University of Southampton School of Medicine
- Maria Scatigna**
University of L'Aquila
- John Seeger**
Harvard Medical School and Harvard School of Public Health
- Katherine Seib**
Emory University
- Linda Selvey**
Curtin University
- Fengping Shan**
School of basic medical science, China Medical University
- Ananda Giri Shankar**
National Health Service
- Hitt Sharma**
Serum Institute of India Ltd
- Angela Shaulov Kask**
University of Washington School of Medicine

- Jin-Xiong She**
Augusta University
- Mark Shelly**
University of Rochester
- Vicky Sheppard**
NSW Department of Health
- Nian-Min Shi**
Beijing Chaoyang District Center for Disease Control and Prevention
- Son Moon Shin**
Cheil General Hospital
- Mary Short**
University of Houston Clear Lake
- John Schiller**
National Cancer Institute
- Melanie Schuster**
Robert Koch Institute
- Edson Silva**
Fundação Oswaldo Cruz
- Jeong-Im Sin**
School of Medicine, Kangwon National University
- Hans-Christian Slotved**
Staten Serum Institute
- Alan Smith**
Archimedes Pharma
- Jo Southern**
Health Protection Agency
- David Spiro**
NIH/NIAID
- Ruchi Srivastava**
University of California Irvine
- Elizabeth Stier**
Boston University School of Medicine
- Melissa Stockwell**
Columbia University
- Julia Stowe**
Health Protection Agency
- Bryan Strauss**
Cancer Institute of Sao Paulo-ICESP
- Lynne Sturm**
Indiana University
- Hongyan Sui**
National Cancer Institute
- Sheena Sullivan**
WHO Collaborating Centre for Reference and Research on Influenza at the Peter Doherty Institute for Infection and Immunity
- Caijun Sun**
Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences
- Manika Suryadevara**
SUNY Upstate Medical University
- Gerd Sutter**
Ludwig-Maximilians-University
- George Syrogiannopoulos**
University of Thessaly
- Silvio Tafuri**
Aldo Moro University of Bari
- Litjen Tan**
Immunization Action Coalition
- De-chu Tang**
VaxDome LLC
- Haidong Tang**
University of Texas Southwestern Medical Center
- Meltem Tasbakan**
Ege University Faculty of Medicine Department of Infectious Disease, Izmir, Turkey
- Jacqueline Tate**
Centers for Disease Control and Prevention
- Michael Tatley**
University of Otago
- Michael Teng**
University of San Francisco
- Stephen Thomas**
Walter Reed Army Institute of Research
- Gengwen Tian**
Driscoll Children's Hospital
- Huaiyu Tian**
Beijing Normal University
- Milene Tino-De-Franco**
Instituto Butantan
- Daisuke Tokuhara**
Osaka City University Graduate School of Medicine
- Nuria Torner**
CIBER Epidemiologia y Salud Pública (CIBERESP)
- Bertrand Toussaint**
TheREX, TIMC-IMAG UMR5525 Université Joseph Fourier
- Andrea Trevisan**
University of Padova
- Hung Trinh**
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF)
- Stephanie Troy**
Eastern Virginia Medical School
- Cecilia Trucchi**
University of Genoa
- S?awomir Tubek**
Voivodship Hospital in Opole
- Jose Tuells**
Universidad de Alicante, Spain
- Nikki Turner**
University of Auckland
- Kenneth Ugen**
University of South Florida
- Johan Van den Bergh**
University of Antwerp, Vaccine & Infectious Disease Institute
- Jan-Willem Van der Laan**
Senior Assessor Pharmacology-Toxicology, Medicines Evaluation Board, The Netherlands
- Nicoline Van der Maas**
National Institute for Public Health and the Environment
- Olivier Van Der Meer**
GSK Vaccines
- Corinne Vandermeulen**
KU Leuven
- Kirsten Vannice**
World Health Organization
- Jose Ignacio Vargas**
School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
- Javier Vázquez**
Instituto de Salud Carlos III, Madrid, Spain
- Baruch Velan**
The Gertner Institute for Epidemiology and Health Policy Research
- Alba Vilajeliu**
GAVI
- Paolo Villari**
Sapienza University of Rome
- Parreño Viviana**
Instituto de Virología
- Simonetta Viviani**
Independent Advisor on Vaccines, Epidemiology and Public Health
- Barry Walker**
Aeras
- Chengbin Wang**
Centers for Disease Control and Prevention
- Ling Wang**
Faculty of Preventative Medicine, Fourth Military Medical University
- Ting Wang**
Anhui Medical University
- Xuan-Yi Wang**
Fudan University
- Ya-Feng Wang**
National Keng Fung University
- Yonglu Wang**
Lanzhou Veterinary Research Institute, CAAS
- Brian Ward**
McGill Univ, Div of Infectious Diseases
- Jeremy Ward**
Aix-Marseille University
- Mary Warrell**
University of Oxford
- Michael Watson**
Valera
- Judith Weiner**
CDC - NCIRD
- Eric Weintraub**
Centers for Disease Control and Prevention
- Astrid Westendorf**
University Hospital Essen
- Christopher J. Wheeler**
Cedars-Sinai Medical Center, 110 N. George Burns Road, Davis 2097, Los Angeles, CA 90048, USA
- Henry Wilde**
Chulalongkorn University
- Annelies Wilder-Smith**
National University Hospital Singapore
- Kerrie Wiley**
University of Sydney Medical School
- Diane Williamson**
DSTL Porton Down
- Kumanan Wilson**
Ottawa Hospital Research Institute; University of Ottawa
- Carl Heins Wirsing von Konig**
Institut für Hygiene und Labormedizin

Rosa Wong-Chew

National Autonomous University of Mexico

Hao Wu

Amgen

Shu-Ju Wu

Department of Nutrition and Health Sciences, Chang Gung University of Science and Technology

Aiqiang Xu

Shandong Center for Disease Control and Prevention

Xuequn Xu

Texas Tech University Health Sciences Center

Lifei Yang

University of Washington

Catherine Yen

Centers for Disease Control and Prevention

Pinar Yıldız

Eskisehir Osmangazi University Faculty of Medicine Department of Internal Medicine, Eskisehir, Turkey

Melinda Yushak

Emory University

Mustapha Zeddou

University of Liege

Jun Zhang

Xiamen University

Xiaoshu Zhang

Gansu Center for Disease Control and Prevention(China)

Qinjian Zhao

Xiamen Univ. China

Bo-Jian Zheng

University of Hong Kong

Fan Zhou

University of Bergen

Yi-Hua Zhou

Nanjing University Medical School

Bingdong Zhu

Pathogen Biology

Fengcai Zhu

Jiangsu Provincial Center for Disease Prevention and Control

 Submit an article   



Editor's Corner

Editorial

Letter from the editor >

Page: 1

Published online: 26 Jan 2017

130	3	0
Views	CrossRef citations	Altmetric

Editorial

Human Vaccines & Immunotherapeutics awards Top Reviewer of the Year >

Ronald Ellis & Adam Weiss

Pages: 2-8

Published online: 26 Jan 2017

627	0	0
Views	CrossRef citations	Altmetric

News, Policy & Profiles

News

Human Vaccines & Immunotherapeutics: News >

Pages: 9-10

Published online: 26 Jan 2017

82	0	0
Views	CrossRef citations	Altmetric

[Submit an article](#)   

▼ A view from the virology research laboratory >

John Oxford

Pages: 11-14

Published online: 25 Aug 2016

148	0	1
Views	CrossRef citations	Altmetric

Profile

Immune Design >

Jan ter Meulen & Stephen R. Brady

Pages: 15-16

Published online: 04 Jan 2017

230	0	0
Views	CrossRef citations	Altmetric

Editorial

Article

Vaccine delivery systems >

Ryan F. Donnelly

Pages: 17-18

Published online: 26 Jan 2017

132	0	0
Views	CrossRef citations	Altmetric

Reviews

Review

From discovery to licensure, the Adjuvant System story >

Nathalie Garçon & Alberta Di Pasquale

[Submit an article](#)   

1913	30	1
Views	CrossRef citations	Altmetric

Review

Current prospects and future challenges for nasal vaccine delivery >

Helmy Yusuf & Vicky Kett

Pages: 34-45

Published online: 09 Dec 2016

497	6	2
Views	CrossRef citations	Altmetric

Commentary

Article commentary

Presentation matters: Buffers, packaging, and delivery devices for new, oral enteric vaccines for infants >

Manjari Lal & Courtney Jarrahan

Pages: 46-49

Published online: 07 Nov 2016

350	1	0
Views	CrossRef citations	Altmetric

Research Paper




Article

Dissolving microneedles for DNA vaccination: Improving functionality via polymer characterization and RALA complexation >

Grace Cole, Joanne McCaffrey, Ahlam A. Ali, John W. McBride, Cian M. McCrudden, Eva M. Vincente-Perez, Ryan F. Donnelly & Helen O. McCarthy

Pages: 50-62

 Submit an article   

 Views |  CrossRef citations |  Altmetric

Review

Review

Potential applications of nanoparticles in cancer immunotherapy >

Yimei Jia, Abdelwahab Omri, Lakshmi Krishnan & Michael J. McCluskie

Pages: 63-74

Published online: 23 Dec 2016

787	5	0
Views	CrossRef citations	Altmetric

Research Paper

Article

Two-dose seasonal influenza vaccine coverage and timeliness among children aged 6 months through 3 years: An evidence from the 2010–11 to the 2014–15 seasons in Zhejiang province, east China >

Yu Hu, Yaping Chen & Bing Zhang

Pages: 75-80

Published online: 17 May 2017

149	3	0
Views	CrossRef citations	Altmetric

Article

Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model >

Ming-Chin Yang, Elise Chia-Hui Tan & Jian-Jhih Su

Pages: 81-89

Published online: 21 Nov 2016

 Submit an article   

Article

Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats >

Camille Planty, Corey P. Mallett, Kevin Yim, Jorge C. G. Blanco, Marina Boukhvalova, Thomas March, Robbert van der Most & Eric Destexhe

Pages: 90-102

Published online: 21 Nov 2016

297	2	1
Views	CrossRef citations	Altmetric

Article

Correlates of influenza vaccine uptake among community-dwelling older adults in Brazil >

Fabíola Bof de Andrade PhD, Ana Paula Sayuri Sato, Roudom Ferreira Moura & José Leopoldo Ferreira Antunes

Pages: 103-110

Published online: 17 May 2017

158	0	1
Views	CrossRef citations	Altmetric

Article

Reassortment of high-yield influenza viruses in vero cells and safety assessment as candidate vaccine strains >

Jian Zhou, Fan Yang, Jinghui Yang, Lei Ma, Yina Cun, Shaohui Song & Guoyang Liao

Pages: 111-116

Published online: 17 May 2017

REVIEW

Current prospects and future challenges for nasal vaccine delivery

Helmy Yusuf^a and Vicky Kett^b

^aSchool of Pharmacy, Queen's University of Belfast, Belfast, Antrim, UK; ^bSchool of Pharmacy, Queen's University of Belfast, Belfast, Antrim, UK

ABSTRACT

Nasal delivery offers many benefits over traditional approaches to vaccine administration. These include ease of administration without needles that reduces issues associated with needlestick injuries and disposal. Additionally, this route offers easy access to a key part of the immune system that can stimulate other mucosal sites throughout the body. Increased acceptance of nasal vaccine products in both adults and children has led to a burgeoning pipeline of nasal delivery technology. Key challenges and opportunities for the future will include translating *in vivo* data to clinical outcomes. Particular focus should be brought to designing delivery strategies that take into account the broad range of diseases, populations and healthcare delivery settings that stand to benefit from this unique mucosal route.

ARTICLE HISTORY

Received 7 July 2016
Revised 9 September 2016
Accepted 18 September 2016

KEYWORDS

influenza; mucosal; nasal;
needle-free; vaccine

In this review the current state of the art in nasal vaccine delivery will be described along with future prospects. A brief introduction to the anatomy and physiology of the nasal cavity will highlight the advantages and disadvantages of the route. Encapsulation and presentation methods along with particular formulation considerations for the nasal route will also be discussed.

There are many mucosal routes which have been regarded as potential sites for vaccine delivery such as oral, nasal, pulmonary, conjunctival, rectal and vaginal mucosa. However, for practical and cultural reasons researchers have tended to focus only on oral, nasal, and pulmonary administration.¹ Needle-free vaccines offer many advantages over traditional vaccination approaches including convenience, cost, ease of administration and disposal.

There are several needle free methods of vaccination such as transdermal delivery and mucosal delivery.^{2,3} Mucosal immunization has been successfully used in human vaccination. The human mucosal immune system is large and specialized in performing inspection for foreign antigens to protect the surfaces themselves and of course human body interior. Since most infections affect or start from mucosal surfaces, using a mucosal route of vaccination is of great interest and provides a rational reason to induce a protective immune response.³ Nasal delivery of vaccine offers an easily accessible route to the immune system.

The nose has the function of olfactory detection (sense of smell) and also filtration, humidification and temperature control of air as it enters the respiratory system. Moving from front to back the areas of the nasal cavity are the nasal vestibule, the respiratory region, and the olfactory region. The nasal cavity is divided by the septum to form the left and right nares, which lead into the left and right choana before opening onto the nasopharynx at the top of the throat. The turbinates bound the

nasal walls and are responsible for air conditioning and the large mucosal surface area of the nasal cavity. The nose is also the main port of entry for many pathogens. The first barrier to foreign bodies is hair at the entrance to the nares, the nostrils, which successfully keeps out larger particles. The entire surface of the nasal cavity is covered in a mucus layer, which traps smaller particles. Mucus is an aqueous, viscoelastic and adhesive gel⁴ that contains several types of mucins (abbreviated to MUC) MUC1, MUC4, MUC5A and MUC5B, MUC16, that are produced by either goblet cells or mucus subglands.^{5,6} Cilia perform a mechanical clearing role termed mucociliary clearance by beating and thus transporting the mucus blanket with entrapped pathogens to the back of the throat at a rate of 5–6 mm per minute, either to be destroyed in the stomach or expectorated via sneezing and/or coughing. This function minimises the amount of particles able to enter the body through the mucosal surface.⁷ The nasal route has been used to deliver vaccines for respiratory infections and sexually transmitted infections.⁸ The rationale for targeting mucosal tissue in the genital tracts can be attributed to the mucosal immune system.

The mucosal immune system

The mucosal immune system provides local protection against pathogens that enter the body through the mucosal membranes. The mucosal immune activities are associated with lymphoid tissues, i.e. mucosa-associated lymphoid tissue (MALT), which is present in mucosal tissue in the nose, lungs, gastrointestinal tract and vaginal/rectal surfaces.⁹ The MALT is classified into specific subcompartments, depending on the location, including the gut-associated lymphoid tissue (GALT), nasopharynx-associated lymphoid tissue (NALT),¹⁰ bronchus-associated lymphoid tissue (BALT). The mucosal routes commonly used for vaccination strategies are depicted in Fig. 1.

CONTACT Vicky Kett v.kett@qub.ac.uk School of Pharmacy, Queen's University of Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom.

Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/khvi.

© 2017 Taylor & Francis




Figure 1. Routes of mucosal vaccination within the mucosa-associated lymphoid tissue (MALT), with several subcompartments including: the nasopharynx-associated lymphoid tissue (NALT), bronchus-associated lymphoid tissue (BALT), gut-associated lymphoid tissue (GALT) and genital tract-associated lymphoid tissue, reproduced from Lycke et al, 2012.¹²⁵

The mucosal immune systems are protected by immune cells that populate the region along the mucosal surfaces, and also epithelial cells and mucus that acts as physical barrier before the pathogen gain access to the underlying tissues.

Respiratory epithelial cells

The epithelial cell layers cover the mucosal surfaces including the respiratory, gastrointestinal and urogenital tracts exposed to the outer environments. The epithelial cell layer acts as a barrier that is equipped with some supporting elements such as the mucus and cilia in preventing penetration of pathogens (Fig. 2).

Furthermore, the epithelial cells can detect and uptake pathogenic organisms and/or antigenic components by performing nonspecific endocytosis or interacting with pattern recognition receptors such as Toll-like receptors (TLRs).¹¹⁻¹⁴ The epithelial cells together with lymphocytes and underlying antigen

presenting cells (e.g. dendritic cells (DCs) and macrophages), cytokines and chemokines perform an innate, non-specific and adaptive immune response to encounter the invasion of pathogenic organisms or immunogenic substances.^{14,15}

Nasopharynx-associated lymphoid tissue (NALT)

The NALT can be simply defined as organized mucosal immune system in the nasal mucosa that consist of lymphoid tissue, B cells, T cells and antigen presenting cells (APCs) and are covered by an epithelial layer containing memory (M) cells.¹⁶ M cells are present in the epithelial cell layers and have specialization in transporting antigen across the epithelium.^{17,18}

Whenever the nasal mucosa is exposed to pathogens or antigenic substances, the intruder will interact with the mucosal immune system. The type of interaction is highly dependent on the characteristics of the antigen. The pathogen or




Figure 2. Structure and function of respiratory epithelial cells; equipped with mucus layer (not shown) and ciliated cells, reproduced from Grassin-Delyle (2012)¹⁴³.

immunogenic substances may be able to pass through the nasal epithelium and interact with the APCs such as macrophages and DCs. These APCs will process the antigen and migrate to the lymph node where the immunogenic portion will be presented to the T cells. This marks the activation of the immune response cascade. A soluble antigen might be recognized by the APCs,¹⁹ while particulate antigen is generally taken up by the M cells and transported to the NALT.²⁰ The NALT is also drained to the lymph node where further antigen processing will occur. A schematic representation of this process in more detail mechanisms is presented in Fig. 3.²¹

Immunoglobulin A (IgA)

In addition to the MALT, the mucosal immune system also produces the antibody immunoglobulin A (IgA), that plays an

important role in mucosal immunity at mucosal surfaces.²² IgA constitutes up to 15 % of the total immunoglobulin, which is predominantly present in external secretions including the mucus in the bronchial, urogenital and digestive tracts, saliva and tears.²³ It was found that the production of IgA in humans could be over 1 mg/ml in secretions associated with the mucosal surfaces.¹⁸ A small amount of IgA can be found in the serum while most of the IgA is located in external secretions known as secretory IgA (sIgA).²⁴ IgA consist of a dimer or tetramer, a joining J-chain polypeptide and a polypeptide chain called the secretory component.^{24,25} IgA has several functions in mucosal defense including the entrapment of antigens or pathogens in mucus to prevent them from direct contact with the mucosal surface.^{15,26} In addition, sIgA may also block or provide steric hindrance to surfaces of pathogenic molecules that may inhibit their attachment to the epithelium.²⁷




Figure 3. Pathways demonstrating how particulate antigen triggers local immune response in the nasal mucosa and systemic immune response via the NALT, adapted from Csaba (2009)²¹.

The predominance of IgA in mucosal areas is a result of mutual collaboration between plasma cells and epithelial cells. The activated plasma cells in the lamina propria, adjacent to mucosal surfaces produce polymeric IgA (pIgA), while the epithelial cells in the mucosal surfaces express an Ig receptor called the polymeric Ig receptor (pIgR). The released pIgA from activated plasma cells binds to pIgR, and is then taken up into the cell via endocytosis. IgA is transported across mucosal epithelial cells before being released onto the luminal surface of the epithelial cells. Proteolysis cleavage of the pIgR allows IgA to be secreted into mucosal secretions.^{15,25,28}

Mucosal vaccines

New vaccine formulations should be able to induce innate and adaptive immune response; involving antigen-specific memory T and B cells that will respond effectively to the invading pathogens.^{29,30} Interaction with pathogens or antigens can produce the IgA secretion as an antibody response.³¹ Intracellular antigens, can be produced by invading viruses that replicate within the host cell, or derive from cytoplasmic bacteria, while the extracellular antigens include bacteria, parasites, and toxins in the tissues. Intracellular antigens are generally processed in the host cells, coupled to a major histocompatibility complex-I (MHC-I), a cell surface molecule, and transported to the cell surface.^{32,32} The presence of MHC-I on the cell surface will lead to activation of CD8+ T-cells to become cytotoxic T-lymphocytes (CTLs). Extracellular antigens are endocytosed and presented on MHC-II molecules for activation of CD4+ T-helper (Th) cells.³²⁻³⁴

The activation of Th cells will release a specific set of cytokines that modulate the B cell and CD8+ CTL immune response, depending on the nature of the stimulant.³⁵ Th cell types Th-1, Th-2 or Th-17 will be induced accordingly. A Th-1 response develops in the presence of interleukin 12 (IL-12), which is in turn synthesized primarily by DCs and/or natural killer (NK) cells in the presence of bacteria or virus. The Th-1 response is marked by the production of the Th-1 cytokines e.g., interferon-gamma (IFN- γ) and tumor necrosis factor- β (TNF- β). A Th-2 response is driven by the presence of IL-4 and results in the production of specific cytokines IL-4, IL-5, IL-9 and IL-13.³⁶ It can be seen that the production of IL-4 generates a feedback loop that results in increased generation of a Th-2 response at the local site.

Nasal vaccination can also result in stimulation of Th-17 CD4+ cells. Th-17 cells are responsible for the secretion of the proinflammatory interleukins IL-17A and IL-22, as well as IL-17F and IL-21. It is known that the Th-17 family of cytokines respond to extracellular bacterial and fungal pathogens, and Th-17 cells enhance generation of Th-1 cells through an increased IFN- γ activation giving rise to a Th-1/Th-17 immune response that activates macrophages and other innate responses.³⁶⁻³⁸ Stimulation of epithelial cells by the Th-17 family of cytokines can aid tissue repair and secretion of antimicrobial peptides, which can exert a protective effect in pulmonary infection.³⁹ There is contradictory evidence, however, regarding the role of Th-17 response in nasal immunization. Early work on the role of Th polarization in nasal immunization indicated that this route always promotes a Th-17 response.⁴⁰ Later

research has indicated that the response is more nuanced, with some contradictory evidence regarding advantages and disadvantages of IL-17A induction.^{41,42,43}

Predominance of one set of cytokines over the other is generally indicative of polarization of Th responses, for example the presence of IL-4 and absence of IFN- γ indicate a classical Th-2 polarized immune reaction⁴⁴ although these cytokines can also be released at the same time.^{45,46,47} The varying cytokine profiles related to CTL and antibody production are fundamental in affording protection against a specific pathogen. Specific macrophage activation was found to play a crucial role in the eradication of Mycobacterium tuberculosis bacterial infections,⁴⁸ showing that the induction of specific immune responses may play a key role in determining whether a given vaccine product is effective.

The recently discovered innate lymphoid cells (ILCs) act as an early source of cytokines to regulate and direct mucosal immune responses.⁴⁹ Unlike B or T cells, however, they do not exhibit antigen specificity. Group 1 ILCs (ILC1s) include NK cells and produce Th-1 type cytokines IFN- γ and tumor necrosis factor- α (TNF- α); group 2 ILCs (ILC2s) produce Th-2 type cytokines IL4, IL-5 and/or IL-13, while group 3 ILCs (ILC3s) include lymphoid tissue inducer cells that produce Th-17 type cytokines IL-17 and/or IL-22. Both ILC1s and ILC3s have been implicated in type 1 and Th17 cell-mediated immunity and disease.⁵⁰ Because they are involved in early release of cytokines at mucosal sites, ILCs have been implicated in directing immune response at the mucosal surface, as shown by a number of recent studies.^{51,52} NK cells and ILC1-like cells damped the immune response after vaginal administration of ovalbumin and cholera toxin to mice.⁵³ NK cells have been shown to enhance Th proliferation through IFN- γ production,⁵⁴ while ILC2s play a role in directing Th-2 response.⁵⁵ There is also evidence that ILCs can act as APCs, although this may be specific to the lymphoid tissue site involved and is thought to occur to a lesser extent than through the professional APCs.⁵⁵ Finally the regulatory T-cells (Tregs) play a role in ILC and Th communication,⁵⁴ as well as helping to directly control Th response, which is particularly important in autoimmune dysfunction discussed later.⁵⁶

Advantages of nasal vaccine delivery

The nasal route has great potential for vaccination due to the organized immune systems of the nasal mucosa. The nasal epithelium encloses follicle-associated lymphoid tissues that are important in inducing mucosal immune response. The immune cells such as nearby B-cells can produce IgA at the mucosal sites where the respiratory pathogens invade.⁵⁷ Many published studies have shown that nasally administered vaccines induce serum IgG and mucosal IgA that are important for deliberating enhanced efficacy of vaccine.^{57,58} The enhanced induction of mucosal IgA antibodies has been shown to play a significant role in neutralizing pathogens such as *Streptococcus pneumoniae*⁵⁹ and measles viruses⁶⁰ and preventing further infection. Moreover, intranasal immunization has also been reported to induce cross-reactive antibodies that might be indicative of cross-protection.^{61,62} This effect can make vaccines more efficient by reducing the number of vaccinations required since

cross-protective vaccines may produce cross-reactive antibodies that recognize more than one antigen. Given the high cost of many antigen production systems this offers a distinct advantage over other routes.

Therapeutic vaccines

While much of the work on nasal vaccine delivery is currently focused on prophylactic vaccines, the access that the nasal route provides to the mucosal immune system also has relevance for therapeutic vaccines used to treat rather than prevent disease. Nasal immunotherapy for treatment of various cancers and Alzheimer are currently generating much interest.^{63,64} A particular focus is the use of therapeutic vaccines for the treatment of autoimmune diseases such as type I diabetes, atherosclerosis, multiple sclerosis, rheumatoid arthritis, lupus and Crohn's disease. These are caused by unchecked immune response to molecules, termed self-antigens, that are capable of inducing an immune response in a host but should not induce an immune response in a healthy individual that produces them, whereas undesirable response to innocuous environmental antigens gives rise to allergy. The autoimmune and inflammatory response is governed by regulatory T-cells (Tregs), with poor function or reduced numbers of Tregs being associated with autoimmune disease. Treatments for this family of diseases are often non-specific, or use immune suppressants that increase susceptibility to infection. Development of effective therapeutic vaccine would correct the inappropriate immune response through generation of tolerance to the self-antigen(s).⁶⁵ Treg cells that express the forkhead box P3 transcription factor are known as FoxP3+T-cells, with dysfunction of this subset of Tregs being implicated in a range of chronic inflammatory disorders.⁶⁶ It has long been known that oral delivery is effective in generating antigen tolerance, through deliberate introduction of the antigen to food.⁶⁷ More recently it has been shown that a similar tolerance induction can be achieved via nasal delivery through activation of the DCs in the draining lymph nodes to enhance induction of FoxP3+T-cells.⁶⁸ Examples of successful nasal delivery include immunization to suppress atherosclerosis^{69,70} and arthritis.⁷¹ The effect of adjuvant on tolerance is discussed in a later section.

Formulation approaches

Current nasal formulations include, solutions (drops or sprays), powders, gels and solid inserts.⁷² Solutions are often described in the literature as they are both the easiest way of formulating a vaccine for an *in vivo* study or clinical trial, and are the easiest to administer for example in mice where the liquid is often pipetted directly into the nostril. In humans this often means that the subject either has to remain laying down or with their head held back for a period of time after administration, which is not realistic in a mass vaccination setting. Sprays are easier to administer and deliver vaccine further into the nasal cavity, but may still leak out of the nostril or drip into the oral cavity. Including a gelling agent in the formulation that is either mucoadhesive or able to penetrate through mucus offers increased residence time, while advantages of solid formats such as powders or solid inserts include ease of manufacture

and stability, while liquids are more prone to degradation. Taste may also be a factor as formulations may travel into the oral cavity, although given that vaccines tend to be administered once or twice only, this is less of an issue than for medicines that are taken on a regular basis.

A range of naturally-occurring, synthetic and semi-synthetic polymers have been investigated as gelling agents in nasal delivery of vaccine. Administering as a gel should improve retention, although there is ongoing debate as to whether positively charged or anionic polymers offer better uptake. Those that have the ability to adhere to mucosal surfaces and selectively target M cells or APCs, should be the most effective.^{18,26} Chitosan has been much investigated, and is a polysaccharide manufactured from chitin found in crustacean shells or fungi by a deacetylation process. Because of the range of sources this polymer is available in a range of molecular weights, but all are made up of repeating units of glucosamine and N-acetylglucosamine and bear a positive charge making it mucoadhesive. Varying the degree of deacetylation affects the charge, as does methylation. Methylating chitosan offers some advantages for mucosal delivery.

Powder formats have the advantage of increased stability over their liquid counterparts and ability to target further into the nasal cavity. An example of this is the Anthrax spray-dried powder formulation suitable for mass vaccination in developed and developing world settings.⁷³ Possible disadvantages of powders include the ease and cost of administration if specialist applicators are required. Solid inserts are tablets designed to dissolve when in contact with mucus and have been investigated for vaginal delivery in humans and nasal delivery in live-stock animals,^{74,75} and have many similarities with sublingual formulations.

Soluble antigens tend to be less immunogenic than particulate formulations, additionally encapsulating antigen into particles may improve the transport of the antigens across the nasal mucosa. For this reason there has been a great interest in developing particulate systems as carriers for vaccine products.⁷⁶⁻⁷⁸ Aspects such as vaccine formulations and delivery strategies are important in designing new vaccines so that efficient induction of the innate and adaptive immune response can be obtained according to the target pathogen.^{18,26} Particulate delivery systems that can imitate pathogens such as polymeric nanoparticles and liposomes are considered a promising approach for nasal vaccine delivery.

Nanoparticles are particles in the nanometer 1×10^{-9} m size range and can be made of polymers such as chitosan, alginate or synthetic co-polymers such as poly(lactic-co-glycolic acid) (PLGA). Varying the molecular weight and/or ratio of lactic to glycolic acid affects the rate of degradation enabling rate of release to be controlled. But PLGA nanoparticles bear a negative charge, which is not compatible with mucosal delivery, hence the plethora of papers investigating various coatings or modifications to adjust this. Those with positive charge and enhanced residence have tended to give the best immunological responses with high serum antibody titers and sIgA levels.⁷⁹ Poly(lactic acid) (PLA) and polyethylene glycol (PEG) can also be combined to form co-block polymers able to incorporate antigen,⁸⁰ varying the molecular weight of the PEG and/or ratio of

PEG to PLA alters physicochemical characteristics, release and hence efficacy.⁸¹

Other polymers investigated include pullulan, a naturally occurring polysaccharide copolymer made up of maltotriose subunits from fungus;⁸² pectin, a naturally occurring polysaccharide found in fruits; and the biodegradable synthetic polymer polycaprolactone.⁸³

Liposomes are nano- or micrometre sized particles made up of one or more lipid bilayers, which have the ability to incorporate antigen at their surface or inside the aqueous core. There are numerous examples of coated and un-coated liposomal formulations used to deliver vaccine intranasally in a range of formats.⁸⁴⁻⁹⁰ Chen showed that trimethylchitosan-coated liposome powders offered improved uptake in ex vivo nasal penetration studies when compared with the same liposomes coated in chitosan.⁹¹ Liposomes that also comprise lipid or other material derived from virus are known as virosomes, with material from influenza virus such as hemagglutinin (HA) and neuraminidase being commonly used.⁹²⁻¹⁰²

Currently there is more evidence to support the hypothesis that particles smaller than 300nm are the most effective at crossing mucus,¹⁰³ but there is also evidence to suggest that larger particles are also able to penetrate. Results from intranasal administration of mucoadhesive microparticles suggest that penetration of the entire particle may not be necessary to induce an immune response.¹⁰⁴ It is likely that the overall combination of size and charge are key to achieving maximum immunological effect. Some examples of particulate delivery systems investigated for nasal delivery of vaccine are shown in Table 1.

Adjuvants

Some materials added to form gels or particles may act as adjuvants as well as delivery vehicles. Alternatively, adjuvants may be added as a separate component to a vaccine product. Adjuvants are materials added to a vaccine to boost the immune response and may also reduce the amount of antigen required to elicit an immune response. Alum is often used in traditional vaccines but is not effective when administered mucosally. Judicious choice of adjuvant can direct the arm of the immune system, as described previously. Often particulate delivery systems are believed to confer both the benefits of optimised delivery across mucus/mucosal tissue and inherent adjuvanting effects. Many studies have investigated these abilities and ascribed immune boosting response to one, other or both qualities.²⁶

Mucosal adjuvants that have been tested for intranasal vaccine delivery including: MF59 emulsion (containing squalene oil, the surfactants Span 85 and Tween 80 and citrate buffer),^{105,106} lipopolysaccharide,^{84,107} TLR agonists,^{41,108,109} chitosan,¹¹⁰ trimethylchitosan,^{91,110} bacterial outer membrane protein¹¹¹ and cholera toxin¹¹² or heat-labile enterotoxin (LT) from *E.coli*.¹¹³ Some side effects have been found with the use of bacterial toxin when given intranasally, including Bell's palsy (Facial paralysis) and other adverse events related to disorders of the facial nerves.¹¹⁴⁻¹¹⁶ It has been suggested that the central nervous system was involved in the palsy as the bacterial toxin was re-directed into the brain.^{115,117} Thus, the use of LT as

vaccine adjuvant is no longer recommended. Mast cell activators such as compound 48/80 (C48/80) have shown promise in Anthrax vaccine.⁷³ As described previously, adjuvants can help to polarize immune response and this effect should be taken into account when considering adjuvant for a particular vaccine type. Mice immunized with an influenza vaccine adjuvanted with a synthetic TLR-4 agonist via the nasal route, exhibited a transient, enhanced IL-17A pathology, characterized by weight loss and morbidity, which was significantly greater than observed in mice given no-adjuvanted antigen.⁴¹ The effect of adjuvants on induction of tolerance has also been noted; an intranasal co-administration of hen egg lysozyme with a TLR2 ligand enhanced Th1-type antibodies in one case,¹¹⁸ while another TLR2 ligand, Pam3Cys, was shown to increase the risk of developing autoimmune disease.¹¹⁹ PLGA nanoparticles have been shown to boost tolerance in suppression of arthritis¹²⁰ and further research by the same group has shown that they are responsible for generation of enhanced Treg cell induction.⁶⁸

Current nasal vaccine products

Licensed intranasal vaccines for humans include the influenza vaccines FluMist/FluencTM (MedImmune, MD, USA)¹²¹ and the NasovacTM live attenuated influenza nasal spray manufactured by the Serum Institute of India, which was developed alongside its live attenuated A(H1N1), more commonly known as swine flu.¹²² No serious side effects have been reported associated with the administration of Nasovac indicating its safety,¹²³ although its efficacy data are not sufficiently available yet.¹²⁴ Until recently FluMist was considered one of the most successful intranasal vaccines, it is well tolerated and had exhibited good efficacy.¹²⁵ A runny nose/nasal congestion has been reported as the most common adverse events of Flumist, with mild to moderate in severity.¹²¹ However The US CDC (Centre for Disease Control) Advisory Committee on Immunization Practices (ACIP) recently voted that the Flumist nasal spray live attenuated influenza vaccine (LAIV) (sic), should not be used during the 2016-2017 flu season, based on "data showing poor or relatively lower effectiveness of LAIV from 2013 through 2016."¹²⁶ At the time of writing no further detail was available. It should be noted that a nasal Live Attenuated Influenza Virus (LAIV) influenza vaccine has been used for over 50 y in Russia and previously the USSR. Data published from a study using the Russian intranasal vaccine showed better herd immunity for intranasal LAIV than inactivated vaccine.¹²⁷ Herd immunity is a crucial impact of mass vaccination programs; it is the immunity given to the whole population, even those who have not received a vaccine, because enough of the population (the herd) have received the vaccine that the infection cannot effectively spread. However, it should be noted that the Russian LAIV is administered in 2 doses 3 weeks apart, which increases cost and has the possibility of reducing compliance.

Targeting school age children for influenza has 2 benefits, first this age group tend to have the highest rates of influenza infection. Secondly targeting children reduces infection rates in through transmission from this group, although transmission rates can vary.¹²⁸ In the European Union an intranasal

Table 1. Examples of particulate formulations with published in vivo data.

Particle type	Vaccine	Study type	Key findings	Literature source
Chitosan and HSA (human serum albumin)	Hepatitis B Plasmid DNA	Female C57/BL mice compared with plasmid DNA alone and protein antigen	humoral and mucosal immune response	Lebre et al 2016 ¹³⁹
polycaprolactone /chitosan	Hepatitis B surface antigen (HBsAg)	C57BL/6 mice IN only. Varying doses of HBsAg no comparator formulations	Dose-independent serum IgG and nasal IgA	Jesus et al 2016 ⁸³
TMC	ovalbumin compared with PLGA and TMC-coated PLGA	Female Balb/c compared with PLGA and TMC-coated PLGA (IM and IN)	Serum IgG superior to other IN but inferior to all IM	Slutter et al 2010 ⁷⁹
chitosan and glycol chitosan coated PLGA	HBsAg	Female BALB/c mice compared with chitosan coated PLGA and PLGA, HBsAg-Alum sub-cut.	GC-PLGA NPs could induce significantly higher systemic and mucosal immune response than other IN nanoparticles.	Pawar et al 2013 ¹⁴⁰
PEG-PLA	HBsAg	BALB/c mice compared with PLA nanoparticles and conventional alum-HBsAg based vaccine	Higher systemic and mucosal response than PLA	Jain et al 2009 ⁸⁰
Liposomes	Influenza plasmid DNA (H1N1) hemagglutinin (HA)	BALB/c mice challenge study IN compared with IM DNA alone (IN and IM)	Protective effect against challenge	Wang et al 2004 ⁸⁵
Esterified hyaluronic acid microparticles	Commercial Influenza H1N1 HA and LTK63 or LTR72 adjuvants	mice, rabbits and micro-pigs IN compared with soluble HA + LTK63, or IM with HA	Significantly enhanced serum IgG responses and higher hemagglutination inhibition (HI) titers than other groups	Singh et al 2001 ¹⁰⁴
Glycol chitosan coated liposomes	Hepatitis B Plasmid DNA	BALB/c mice prime boost compared with DNA alone (IN) and HBsAg protein (IM)	Humoral mucosal and cellular response higher than DNA alone. Cellular response better than IM protein antigen	Khatri et al 2008 ¹⁴¹
Liposomes/ hyaluronic acid	Yersinia pestis (plague)	C57BL/6 mice No IM comparison	Th1/Th2 humoral immune response	Fan et al 2015 ⁹⁰
Chitosan-coated PLGA	foot-and-mouth disease plasmid DNA	Challenge study in cattle	Higher mucosal, systemic, and cell-mediated immunity than Chitosan - Inactivated antigen nanoparticles	Pan et al 2014 ¹⁴²
Cationic cholesteryl-group-bearing pullulan	<i>Clostridium botulinum</i> type-A neurotoxin subunit antigen	BALB/c mice	Strong tetanus-toxoid-specific systemic and mucosal immune responses	Nochi et al 2010 ⁸²

influenza vaccine was licensed in 2011. Damm et al explored the possible effect of introducing this product in Germany and concluded that introducing the vaccine to German schoolchildren would lead to a "substantial reduction in influenza-associated disease at a reasonable cost to the German statutory health insurance system."¹²⁹ Researchers looking into the same

question for Thailand reached similar conclusions with provisos based on willingness to pay and contact between age groups.¹³⁰ This study raised the issue of effectiveness across countries where healthcare systems are either new or emerging and differences in rates and timing of seasonal outbreaks. These findings highlight the differences between high and low-

Table 2. Currently marketed technology for nasal delivery.

Name	Company	Presentation	Drug type	Regulatory status	Marketed products	Company web-site
Criticalsorb	Critical Pharmaceuticals	Powder or aerosol	Small molecule – peptide, HGH, insulin	GRAS status?	None	www.criticalpharmaceuticals.com
μco™	Nasal Delivery System Business	Powder-based mucoadhesive drug carrier plus device	Anti-emetic Migraine, flu vaccine	Phase II, Phase I, pre-clinical	None	www.snbl-nds.co.jp/en/
Optinose	Optinose	Powder or liquid plus device	Small molecule	Clinical trials (various)	None	optinose.com/
Kurve	Kurve	Liquid plus device	Includes Alzheimer vaccine	Phase II	None	www.kurvevetech.com
MAD nasal	Teleflex	Liquid plus device	Attachment for syringe to atomize liquids	Device only/ not vaccines	Marketed as stand-alone device	www.teleflex.com
None	Drug Delivery International	Solid insert	Small molecules and insulin	None found	None found	www.bddpharma
FlumistFluenz	MedImmune (AstraZeneca)	Nasal gel	Flu vaccine	FDA & EMA	FlumistFluenz	www.flumistquadrivalent.com/
Bacterial S antigen pores	Tufts University - US	Oral/nasal format not stated	Tetanus toxin and rotavirus VP6 antigen	None	None	www.tufts.edu/
Vaccinetab	Queen's University Belfast, UK	Liposomal liquid, powder or nasal insert	Small molecules and antigen	GRAS	None	www.vaccinetab.com
ChiSys	Archimedes Pharma	Nasal gel	Small molecules and antigen	Phase I, pre-clinical	Small molecule	

middle-income countries and demonstrate the need to carefully evaluate the target population and seasonal factors before designing or selecting a vaccine product.

A recent review describes most of the commonly encountered nasal delivery devices currently on the market.⁷² Additionally, there is a range of nasal delivery strategies at various stages along the pre-clinical-clinical pipe-line, some of these may be suitable for vaccine delivery either in their current formats or with some adaptation. A selection of these is shown in Table 2 and will be described briefly. Criticalorb is a penetration enhancing formulation based on PLGA and PLA, developed by a spin-out from University of Nottingham, UK, currently there are no details for vaccine application. The website of μco^{TM} System (Muco System) shows data for a nasal flu vaccine in a non-human primate immunogenicity study, stating that more sIgA was produced in the mucosal membrane compared to injection and nasal liquid spray, and 4-times greater sIgA than a nasal liquid spray.¹³¹ Optinose is a breath-actuated device for delivering powder or liquid, a schematic of the device has been published in the literature,¹³² as has data on the use of sumatriptan delivered via the Optinose device.^{133,134} Kurve is a device for delivering liquid formulations "via a controlled, turbulent flow,"¹³⁵ the makers have published results of a pilot clinical trial detailing their intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment A,¹³⁶ while Archimedes Pharma developed a chitosan-based formulation, ChiSys[®], that achieved good success in a clinical trial for a Norovirus vaccine.¹³⁷ Because of the proprietary and often pre-approval nature of the devices described (with the exception of Flumist/Fluenz and MAD Nasal), there is a paucity of information regarding design of some of the devices described in this section. The interested reader is referred to the relevant company websites (Table 2), which will offer more current information than is possible in this review.

Conclusion

Safety profiles are yet to be established in humans for many of the formulation approaches described in this review. However, the ever-increasing range of clinical trials indicates the accepted need for nasal vaccines that are easy to administer and offer improved benefits over other mucosal routes in terms of cost of formulation and need for skilled personnel to administer. The obvious benefits of directly stimulating the mucosal immune response are clear, but as yet have not been fully realized with the exception of those for influenza, which demonstrate the efficiency of this route. The recent US CDC press release will no doubt impact on the pharmaceutical industry view of riskiness of nasal formats. But with increased need to immunize large populations, potentially in swift response to pandemics such as avian, swine flu and Ebola there is a clear need to have strategies in place. The interplay between formulation or carrier and adjuvant in directing immune response should be investigated. Unfortunately, the high cost of clinical trials and issues with correlating immune responses in animal models with humans have created a bottleneck. There is a growing body of evidence to suggest that genetic material can be successfully delivered via this route, while recent studies have also

demonstrated the advantages associated with combining the nasal with other routes of delivery or even combining vaccine with microbicide.¹³⁸ This review has focused primarily on prophylactic vaccines but there is encouraging evidence that nasal delivery will have a role to play in the design of therapeutic vaccines for e.g. cancers Alzheimer and autoimmune diseases. The role of presentation is also important when designing pre-clinical studies – instillation of drops is relatively facile even in mice, while more advanced formulations require more careful consideration than those administered via pipette. The design of ex vivo, cell culture or tissue models that provide better prediction of response in humans is extremely desirable. A "one size fits all" approach is not appropriate for vaccine design where factors relating to target population, disease type and mode of infection, will all impact on both formulation and antigen optimization.

Disclosure of potential conflicts of interest

In accordance with Taylor & Francis policy and my ethical obligation as a researcher, I am reporting that both authors are named inventors of the patent covering the technology in the VaccineTab product described herein. VK has a financial interest in the VaccineTab company that may be affected by the research reported in the enclosed paper. I have disclosed those interests fully to Taylor & Francis, and I have in place an approved plan for managing any potential conflicts arising from that involvement.

References

- [1] Giudice EL, Campbell JD. Needle-free vaccine delivery. *Adv Drug Deliv Rev* 2006; 58:68-89; PMID:16564111; <http://dx.doi.org/10.1016/j.addr.2005.12.003>
- [2] Chen D, Endres RL, Erickson CA, Weis KF, McGregor MW, Kawaoka Y, Payne LG. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. *Nat Med* 2000; 6:1187-90; PMID:11017153; <http://dx.doi.org/10.1038/80538>
- [3] Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. *Nat Med* 2005; 11:S45-S53; PMID:15812489; <http://dx.doi.org/10.1038/nm1213>
- [4] Quraishi MS, Jones NS, Mason J. The rheology of nasal mucus: a review. *Clin Otolaryngol* 1998; 23:403-13; PMID:9800075; <http://dx.doi.org/10.1046/j.1365-2273.1998.00172.x>
- [5] Voynow JA, Rubin BK. Mucins, mucus, and sputum. *Chest* 2009; 135:505-12; PMID:19201713; <http://dx.doi.org/10.1378/chest.08-0412>
- [6] Thornton DJ, Rousseau K, McGuckin MA. Structure and function of the polymeric mucins in airways mucus. *Annu Rev Physiol* 2008; 70:459-86; PMID:17850213; <http://dx.doi.org/10.1146/annurev.physiol.70.113006.100702>
- [7] Walker WT, Liew A, Harris A, Cole J, Lucas JS. Upper and lower airway nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and asthma. *Respir Med* 2013; 107:380-6; PMID:23290188; <http://dx.doi.org/10.1016/j.rmed.2012.11.021>
- [8] Thomann-Harwood LJ, Kaeuper P, Rossi N, Milona P, Herrmann B, McCullough KC. Nanogel vaccines targeting dendritic cells: Contributions of the surface decoration and vaccine cargo on cell targeting and activation. *J Controlled Release* 2013; 166:95-105; <http://dx.doi.org/10.1016/j.jconrel.2012.11.015>
- [9] Brandtzaeg P. Function of Mucosa-Associated Lymphoid Tissue in Antibody Formation. *Immunol Invest* 2010; 39:303-55; PMID:20450282; <http://dx.doi.org/10.3109/08820131003680369>
- [10] van de Pavert SA, Mebius RE. New insights into the development of lymphoid tissues. *Nat Rev Immunol* 2010; 10:664-74; PMID:20706277; <http://dx.doi.org/10.1038/nri2832>

- [11] Hargreaves DC, Medzhitov R. Innate Sensors of Microbial Infection. *J Clin Immunol*; 25:503-10; PMID:16380814; <http://dx.doi.org/10.1007/s10875-005-8065-4>
- [12] J Philpott D, E Girardin S, J Sansonetti P. Innate immune responses of epithelial cells following infection with bacterial pathogens. *Curr Opin Immunol* 2001; 13:410-6; PMID:11498296; [http://dx.doi.org/10.1016/S0952-7915\(00\)00235-1](http://dx.doi.org/10.1016/S0952-7915(00)00235-1)
- [13] López-Boado YS, Wilson CL, Hooper LV, Gordon JI, Hultgren SJ, Parks WC. Bacterial Exposure Induces and Activates Matrilysin in Mucosal Epithelial Cells. *The Journal of Cell Biology* 2000; 148:1305-15; PMID:Can't; <http://dx.doi.org/10.1083/jcb.148.6.1305>
- [14] Kagnoff MF, Eckmann L. Epithelial cells as sensors for microbial infection. *J Clin Invest* 1997; 100:6-10; PMID:9202050; <http://dx.doi.org/10.1172/JCI119522>
- [15] Neutra MR, Mantis NJ, Kraehenbuhl J-P. Collaboration of epithelial cells with organized mucosal lymphoid tissues. *Nat Immunol* 2001; 2:1004-9; PMID:11685223; <http://dx.doi.org/10.1038/ni1101-1004>
- [16] Kiyono H, Fukuyama S. NALT- versus PEYER'S-patch-mediated mucosal immunity. *Nat Rev Immunol* 2004; 4:699-710; PMID:15343369
- [17] Corr SC, Gahan CC, Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. *FEMS Immunol Med Microbiol* 2008; 52:2-12; PMID:18081850
- [18] Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. *Nat Rev Immunol* 2006; 6:148-58; PMID:16491139
- [19] Sharma S, Mukkur TK, Benson HA, Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. *J Pharm Sci* 2009; 98:812-43; PMID:18661544
- [20] Illum L. Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? *J Pharm Sci* 2007; 96:473-83; PMID:17117404
- [21] Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. *Adv Drug Deliv Rev* 2009; 61:140-57; PMID:19121350
- [22] Fagarasan S, Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. *Nat Rev Immunol* 2003; 3:63-72; PMID:12511876
- [23] Macpherson AJ, Slack E. The functional interactions of commensal bacteria with intestinal secretory IgA. *Current opinion in gastroenterology* 2007; 23:673-8; PMID:17906446
- [24] Yel L. Selective IgA Deficiency. *J Clin Immunol* 2010; 30:10-6; PMID:20101521
- [25] Snoeck V, Peters IR, Cox E. The IgA system: a comparison of structure and function in different species. *Vet Res* 2006; 37:455-67; PMID:16611558
- [26] Borges O, Lebre F, Bento D, Borchard G, Junginger HE. Mucosal Vaccines: Recent Progress in Understanding the Natural Barriers. *Pharm Res* 2010; 27:211-23; PMID:19953309
- [27] Hutchings AB, Helander A, Silvey KJ, Chandran K, Lucas WT, Nibert ML, Neutra MR. Secretory Immunoglobulin A Antibodies against the $\sigma 1$ Outer Capsid Protein of Reovirus Type 1 Lang Prevent Infection of Mouse Peyer's Patches. *J Virol* 2004; 78:947-57; PMID:14694126
- [28] Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. *Mucosal Immunol* 0000; 1:11-22
- [29] van Ginkel FW, Nguyen HH, McGhee JR. Vaccines for mucosal immunity to combat emerging infectious diseases. *Emerg Infect Dis* 2000; 6:123-32; PMID:10756145
- [30] Talsma SS, Babensee JE, Murthy N, Williams IR. Development and in vitro validation of a targeted delivery vehicle for DNA vaccines. *J Controlled Release* 2006; 112:271-9
- [31] Russell-Jones GJ. Oral vaccine delivery. *J Controlled Release* 2000; 65:49-54; [http://dx.doi.org/10.1016/S0168-3659\(99\)00231-X](http://dx.doi.org/10.1016/S0168-3659(99)00231-X)
- [32] Burgdorf S, Kautz A, Böhner V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. *Science (New York, NY)* 2007; 316:612-6; <http://dx.doi.org/10.1126/science.1137971>
- [33] Brandtzaeg P. Nature and function of gastrointestinal antigen-presenting cells. *Allergy* 2001; 56:16-20; PMID:11298000; <http://dx.doi.org/10.1034/j.1398-9995.2001.00903.x>
- [34] Diebold SS, Cotten M, Koch N, Zenke M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. *Gene Ther* 2001; 8:487-93; PMID:11313828; <http://dx.doi.org/10.1038/sj.gt.3301433>
- [35] Guy B. The perfect mix: recent progress in adjuvant research. *Nat Rev Micro* 2007; 5:505-17; <http://dx.doi.org/10.1038/nrmicro1681>
- [36] Sansonetti PJ, Di Santo JP. Debugging how Bacteria Manipulate the Immune Response. *Immunity* 2007; 26:149-61; PMID:17307704; <http://dx.doi.org/10.1016/j.immuni.2007.02.004>
- [37] Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4(+) T cell responses after vaccination and during Mycobacterium tuberculosis challenge. *Nat Immunol* 2007; 8:369-77; PMID:17351619; <http://dx.doi.org/10.1038/ni1449>
- [38] Keijzer C, Haijema BJ, Meijerhof T, Voorn P, de Haan A, Leenhouts K, van Roosmalen ML, van Eden W, Broere F. Inactivated influenza vaccine adjuvanted with Bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion. *Vaccine* 2014; 32:2904-10; PMID:24598720; <http://dx.doi.org/10.1016/j.vaccine.2014.02.019>
- [39] Rathore JS, Wang Y. Protective role of Th17 cells in pulmonary infection. *Vaccine* 2016; 34:1504-14; PMID:26878294; <http://dx.doi.org/10.1016/j.vaccine.2016.02.021>
- [40] Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA. Intranasal Immunization Promotes Th17 Immune Responses. *J Immunol* 2009; 183:6933-8; PMID:19890060; <http://dx.doi.org/10.4049/jimmunol.0901144>
- [41] Maroof A, Yorgensen YM, Li YF, Evans JT. Intranasal Vaccination Promotes Detrimental Th17-Mediated Immunity against Influenza Infection. *PLoS Path* 2014; 10:e1003875
- [42] McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, Tighe M, Hamada H, Sell S, Dutton RW, et al. IL-10 Deficiency Unleashes an Influenza-Specific Th17 Response and Enhances Survival against High-Dose Challenge. *J Immunol* 2009; 182:7353-63; PMID:19494257; <http://dx.doi.org/10.4049/jimmunol.0900657>
- [43] Hamada H, Garcia-Hernandez MD, Reome JB, Misra SK, Strutt TM, McKinstry KK, Cooper AM, Swain SL, Dutton RW. Tc17, a Unique Subset of CD8 T Cells That Can Protect against Lethal Influenza Challenge. *J Immunol* 2009; 182:3469-81; PMID:19265125; <http://dx.doi.org/10.4049/jimmunol.0801814>
- [44] Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, Hedstrom RC, Rahardjo N, Gay T, Hobart P, et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. *Proc Natl Acad Sci U S A* 2001; 98:10817-22; PMID:11526203; <http://dx.doi.org/10.1073/pnas.181123498>
- [45] Srikiatkachorn A, Chang W, Braciale TJ. Induction of Th-1 and Th-2 Responses by Respiratory Syncytial Virus Attachment Glycoprotein Is Epitope and Major Histocompatibility Complex Independent. *J Virol* 1999; 73:6590-7; PMID:10400756
- [46] Haglund K, Leiner I, Kerksiek K, Buonocore L, Pamer E, Rose JK. High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. *J Virol* 2002; 76:2730-8; PMID:11861840; <http://dx.doi.org/10.1128/JVI.76.6.2730-2738.2002>
- [47] Boyer JD, Cohen AD, Vogt S, Schumann K, Nath B, Ahn L, Lacy K, Bagarazzi ML, Higgins TJ, Baine Y, et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. *J Infect Dis* 2000; 181:476-83; PMID:10669329; <http://dx.doi.org/10.1086/315229>
- [48] D'Souza S, Romano M, Korf J, Wang X-M, Adnet P-Y, Huygen K. Partial Reconstitution of the CD4(+)-T-Cell Compartment in CD4 Gene Knockout Mice Restores Responses to Tuberculosis DNA Vaccines. *Infect Immun* 2006; 74:2751-9; PMID:16622212; <http://dx.doi.org/10.1128/IAI.74.5.2751-2759.2006>
- [49] Walsh KP, Mills KHG. Dendritic cells and other innate determinants of T helper cell polarisation. *Trends Immunol*; 34:521-30; PMID:23973621; <http://dx.doi.org/10.1016/j.it.2013.07.006>

- [50] McKenzie Andrew NJ, Spits H, Eberl G. Innate Lymphoid Cells in Inflammation and Immunity. *Immunity* 2014; 41:366-74; PMID:25238094; <http://dx.doi.org/10.1016/j.immuni.2014.09.006>
- [51] Artis D, Spits H. The biology of innate lymphoid cells. *Nature* 2015; 517:293-301; PMID:25592534; <http://dx.doi.org/10.1038/nature14189>
- [52] von Burg N, Turchinovich G, Finke D. Maintenance of Immune Homeostasis through ILC/T Cell Interactions. *Front Immunol* 2015; 6:416; PMID:26322047; <http://dx.doi.org/10.3389/fimmu.2015.00416>
- [53] Luci C, Bekri S, Bihl F, Pini J, Bourdely P, Nouhen K, Malgogne A, Walzer T, Braud VM, Anjuère F. NKp46+ Innate Lymphoid Cells Dampen Vaginal CD8 T Cell Responses following Local Immunization with a Cholera Toxin-Based Vaccine. *PLoS ONE* 2015; 10:e0143224; PMID:26630176; <http://dx.doi.org/10.1371/journal.pone.0143224>
- [54] Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4(+) T cells via OX40-OX40 ligand interactions. *J Immunol* 2004; 173:3716-24; PMID:15356117; <http://dx.doi.org/10.4049/jimmunol.173.6.3716>
- [55] Mirchandani AS, Besnard AG, Yip E, Scott C, Bain CC, Cerovic V, Salmond RJ, Liew FY. Type 2 Innate Lymphoid Cells Drive CD4(+) Th2 Cell Responses. *J Immunol* 2014; 192:2442-8; PMID:24470502; <http://dx.doi.org/10.4049/jimmunol.1300974>
- [56] Sakaguchi S, Wing K, Miyara M. Regulatory T cells - a brief history and perspective. *Eur J Immunol* 2007; 37:S116-S23; PMID:17972355; <http://dx.doi.org/10.1002/eji.200737593>
- [57] Ramirez K, Wahid R, Richardson C, Bargatzke RF, El-Kamary SS, Szein MB, Pasetti MF. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. *Clin Immunol* 2012; 144:98-108; PMID:22710446; <http://dx.doi.org/10.1016/j.clim.2012.05.006>
- [58] Sealy R, Jones BG, Surman SL, Hurwitz JL. Robust IgA and IgG-producing antibody forming cells in the diffuse NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1. *Vaccine* 2010; 28:6749-56; PMID:20682364; <http://dx.doi.org/10.1016/j.vaccine.2010.07.068>
- [59] Fujikuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, Kiyono H, Fujihashi K. Novel vaccine development strategies for inducing mucosal immunity. *Expert Rev Vaccines* 2012; 11:367-79; PMID:22380827; <http://dx.doi.org/10.1586/erv.11.196>
- [60] Simon JK, Ramirez K, Cuberos L, Campbell JD, Viret JF, Muñoz A, Lagos R, Levine MM, Pasetti MF. Mucosal IgA Responses in Healthy Adult Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles Vaccine. *Clin Vaccine Immunol* 2011; 18:355-61; PMID:21228137; <http://dx.doi.org/10.1128/CVI.00354-10>
- [61] Lijek RS, Luque SL, Liu Q, Parker D, Bae T, Weiser JN. Protection from the acquisition of *Staphylococcus aureus* nasal carriage by cross-reactive antibody to a pneumococcal dehydrogenase. *Proc Natl Acad Sci U S A* 2012; 109:13823-8; PMID:22869727; <http://dx.doi.org/10.1073/pnas.1208075109>
- [62] Jang YH, Byun YH, Lee YJ, Lee YH, Lee K-H, Seong BL. Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses. *J Virol* 2012; 86:5953-8; PMID:22438541; <http://dx.doi.org/10.1128/JVI.07149-11>
- [63] Motohashi S, Okamoto Y, Yoshino I, Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. *Clin Immunol* 2011; 140:167-76; PMID:21349771; <http://dx.doi.org/10.1016/j.clim.2011.01.009>
- [64] Xiao C, Davis FJ, Chauhan BC, Viola KL, Lacor PN, Velasco PT, Klein WL, Chauhan NB. Brain transit and ameliorative effects of intranasally delivered anti-amyloid-beta oligomer antibody in 5XFAD mice. *J Alzheimers Dis* 2013; 35:777-88; PMID:23542865
- [65] Keijzer C, van der Zee R, van Eden W, Broere F. Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseases. *Front Immunol* 2013; 4:245; PMID:23970886; <http://dx.doi.org/10.3389/fimmu.2013.00245>
- [66] Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. *Nat Rev Immunol* 2010; 10:490-500; PMID:20559327; <http://dx.doi.org/10.1038/nri2785>
- [67] Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. *Immunol Rev* 2011; 241:241-59; PMID:21488901; <http://dx.doi.org/10.1111/j.1600-065X.2011.01017.x>
- [68] Keijzer C, Spiering R, Silva AL, van Eden W, Jiskoot W, Vervelde L, Broere F. PLGA nanoparticles enhance the expression of retinaldehyde dehydrogenase enzymes in dendritic cells and induce FoxP3+ T-cells in vitro. *J Controlled Release* 2013; 168:35-40; <http://dx.doi.org/10.1016/j.jconrel.2013.02.027>
- [69] Li H, Ding Y, Yi G, Zeng Q, Yang W. Establishment of nasal tolerance to heat shock protein-60 alleviates atherosclerosis by inducing TGF- β -dependent regulatory T cells. *J Huazhong Univ Sci Technol [Medical Sciences]* 2012; 32:24-30; PMID:22282240; <http://dx.doi.org/10.1007/s11596-012-0004-z>
- [70] Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodtloff D, Rudling M, Ketelhuth DFJ, Gerdes N, Holmgren J, Nilsson J, et al. Intranasal Immunization With an Apolipoprotein B-100 Fusion Protein Induces Antigen-Specific Regulatory T Cells and Reduces Atherosclerosis. *Arterioscler Thromb Vasc Biol* 2010; 30:946-U148; <http://dx.doi.org/10.1161/ATVBAHA.109.202671>
- [71] Broere F, Wieten L, Koerkamp EIK, van Roon JAG, Guichelaar T, Lafeber F, van Eden W. Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. *J Immunol* 2008; 181:899-906; PMID:18606641; <http://dx.doi.org/10.4049/jimmunol.181.2.899>
- [72] Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. *Drug Delivery and Translational Research* 2013; 3:42-62; PMID:23316447; <http://dx.doi.org/10.1007/s13346-012-0108-9>
- [73] Wang SH, Kirwan SM, Abraham SN, Staats HF, Hickey AJ. Stable Dry Powder Formulation for Nasal Delivery of Anthrax Vaccine. *J Pharm Sci* 2012; 101:31-47; PMID:21905034; <http://dx.doi.org/10.1002/jps.22742>
- [74] McInnes FJ, Thapa P, Baillie AJ, Welling PG, Watson DG, Gibson I, Nolan A, Stevens HNE. In vivo evaluation of nicotine lyophilised nasal insert in sheep. *Int J Pharm* 2005; 304:72-82; PMID:16183221; <http://dx.doi.org/10.1016/j.ijpharm.2005.07.025>
- [75] Pattani A, McKay PF, Curran RM, McCaffrey J, Gupta PN, Lowry D, Kett VL, Shattock RJ, McCarthy HO, Malcolm RK. Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form. *Vaccine* 2012; 30:2778-85; PMID:22361120; <http://dx.doi.org/10.1016/j.vaccine.2012.02.004>
- [76] Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. *Nat Rev Immunol* 2010; 10:787-96; PMID:20948547; <http://dx.doi.org/10.1038/nri2868>
- [77] Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. *Adv Drug Deliv Rev* 2008; 60:915-28; PMID:18325628; <http://dx.doi.org/10.1016/j.addr.2007.05.017>
- [78] Koping-Hoggard M, Sanchez A, Alonso MJ. Nanoparticles as carriers for nasal vaccine delivery. *Exp Rev Vaccines* 2005; 4:185-96; PMID:15889992; <http://dx.doi.org/10.1586/14760584.4.2.185>
- [79] Slütter B, Bal S, Keijzer C, Mallants R, Hagensaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Löwik C, et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. *Vaccine* 2010; 28:6282-91; PMID:20638455; <http://dx.doi.org/10.1016/j.vaccine.2010.06.121>
- [80] Jain AK, Goyal AK, Gupta PN, Khatri K, Mishra N, Mehta A, Mangal S, Vyas SP. Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. *J Controlled Release* 2009; 136:161-9; <http://dx.doi.org/10.1016/j.jconrel.2009.02.010>
- [81] Jain A, Massey AS, Yusuf H, McDonald DM, McCarthy H, Kett V. Development of polymeric-cationic peptide composite nanoparticles, a nanoparticle-in- nanoparticle system for controlled gene delivery. *Int J Nanomed* 2015; 7:183-96.

- [82] Nochi T, Yuki Y, Takahashi H, Sawada S-I, Mejima M, Kohda T, Harada N, Kong IG, Sato A, Kataoka N, et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. *Nat Mater* 2010; 9:572-8; PMID:20562880; <http://dx.doi.org/10.1038/nmat2784>
- [83] Jesus S, Soares E, Costa J, Borchard G, Borges O. Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-epsilon-caprolactone based nanoparticles. *Int J Pharm* 2016; 504:59-69; PMID:26976502; <http://dx.doi.org/10.1016/j.ijpharm.2016.03.013>
- [84] de Jonge MI, Hamstra HJ, Jiskoot W, Roholl P, Williams NA, Dankert J, Alphen Lv, van der Ley P. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. *Vaccine* 2004; 22:4021-8; PMID:15364452; <http://dx.doi.org/10.1016/j.vaccine.2004.03.047>
- [85] Wang D, Christopher ME, Nagata LP, Zabielski MA, Li H, Wong JP, Samuel J. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. *J Clin Virol* 2004; 31, Supplement 1:99-106; <http://dx.doi.org/10.1016/j.jcv.2004.09.013>
- [86] Khatri K, Goya AK, Gupta PN, Mishra N, Mehta A, Vyas SP. Surface modified liposomes for nasal delivery of DNA vaccine. *Vaccine* 2008; 26:2225-33; PMID:18396362; <http://dx.doi.org/10.1016/j.vaccine.2008.02.058>
- [87] Amin M, Jaafari MR, Tafaghodi M. Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. *Colloids and Surfaces B-Biointerfaces* 2009; 74:225-9; <http://dx.doi.org/10.1016/j.colsurfb.2009.07.024>
- [88] Heurtault B, Frisch B, Pons F. Liposomes as delivery systems for nasal vaccination: strategies and outcomes. *Exp Opin Drug Delivery* 2010; 7:829-44; PMID:20459361; <http://dx.doi.org/10.1517/17425247.2010.488687>
- [89] Wang HW, Jiang PL, Lin SF, Lin HJ, Ou KL, Deng WP, Lee LW, Huang YY, Liang PH, Liu DZ. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. *Acta Biomater* 2013; 9:5681-8; PMID:23159567; <http://dx.doi.org/10.1016/j.actbio.2012.11.007>
- [90] Fan Y, Sahdev P, Ochyl LJ, J. Akerberg J, Moon JJ. Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens. *J Controlled Release* 2015; 208:121-9; <http://dx.doi.org/10.1016/j.jconrel.2015.04.010>
- [91] Chen KH, Di Sabatino M, Albertini B, Passerini N, Kett VL. The effect of polymer coatings on physicochemical properties of spray-dried liposomes for nasal delivery of BSA. *Eur J Pharm Sci* 2013; 50:312-22; PMID:23876823; <http://dx.doi.org/10.1016/j.ejps.2013.07.006>
- [92] Glück U, Gebbers J-O, Glück R. Phase 1 Evaluation of Intranasal Virosomal Influenza Vaccine with and without Escherichia coli Heat-Labile Toxin in Adult Volunteers. *J Virol* 1999; 73:7780-6; PMID:10438868
- [93] Gluck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. *Vaccine* 2001; 20, Supplement 1:S42-S4.
- [94] Cusi MG, Zurbriggen R, Valassina M, Bianchi S, Durrer P, Valensin PE, Donati M, Gluck R. Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. *Virology* 2000; 277:111-8; PMID:11062041; <http://dx.doi.org/10.1006/viro.2000.0605>
- [95] Durrer P, Gluck U, Spyr C, Lang AB, Zurbriggen R, Herzog C, Gluck R. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. *Vaccine* 2003; 21:4328-34; PMID:14505915; [http://dx.doi.org/10.1016/S0264-410X\(03\)00457-2](http://dx.doi.org/10.1016/S0264-410X(03)00457-2)
- [96] Salleras L, Dominguez A, Pumarola T, Prat A, Marcos MA, Garrido P, Artigas R, Bau A, Brotons J, Bruna X, et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: A prospective cohort study. *Vaccine* 2006; 24:6638-42; PMID:16842892; <http://dx.doi.org/10.1016/j.vaccine.2006.05.034>
- [97] Lambkin R, Oxford JS, Bossuyt S, Mann A, Metcalfe IC, Herzog C, Viret JF, Gluck R. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. *Vaccine* 2004; 22:4390-6; PMID:15474733; <http://dx.doi.org/10.1016/j.vaccine.2003.10.054>
- [98] Hossain MJ, Bourgeois M, Quan F-S, Lipatov AS, Song J-M, Chen L-M, Compans RW, York I, Kang S-M, Donis RO. Virus-Like Particle Vaccine Containing Hemagglutinin Confers Protection against 2009 H1N1 Pandemic Influenza. *Clin Vaccine Immunol* 2011; 18:2010-7; PMID:22030367; <http://dx.doi.org/10.1128/CVI.05206-11>
- [99] Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. *Exp Rev Vaccines* 2010; 9:299-307; PMID:20218858; <http://dx.doi.org/10.1586/erv.09.163>
- [100] Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: Effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. *Vaccine* 2008; 26:6555-63; PMID:18848856; <http://dx.doi.org/10.1016/j.vaccine.2008.09.057>
- [101] de Jonge J, Leenhouts JM, Holtrop M, Schoen P, Scherrer P, Cullis PR, Wilschut J, Huckriede A. Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. *Biochem J* 2007; 405:41-9; PMID:17355227; <http://dx.doi.org/10.1042/BJ20061756>
- [102] Cusi MG. Applications of influenza virosomes as a delivery system. *Human Vaccines* 2006; 2:1-7; PMID:17012895; <http://dx.doi.org/10.4161/hv.2.1.2494>
- [103] Lai SK, Wang Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. *Adv Drug Del Rev* 2009; 61:158-71; <http://dx.doi.org/10.1016/j.addr.2008.11.002>
- [104] Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. *J Controlled Release* 2001; 70:267-76; [http://dx.doi.org/10.1016/S0168-3659\(00\)00330-8](http://dx.doi.org/10.1016/S0168-3659(00)00330-8)
- [105] Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, Katz JM, Praus M, Banzhoff A. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. *N Engl J Med* 2008; 359:1631-3; PMID:18843132; <http://dx.doi.org/10.1056/NEJMc0805274>
- [106] Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59TM adjuvant. *Vaccine* 2008; 26:3209-22; PMID:18462843; <http://dx.doi.org/10.1016/j.vaccine.2008.03.093>
- [107] McAleer JP, Vella AT. Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide. *Trends Immunol* 2010; 31:429-35; PMID:20880743; <http://dx.doi.org/10.1016/j.it.2010.08.005>
- [108] Zonneveld-Huijssoon E, van Wijk F, Roord S, Delemarre E, Meerding J, de Jager W, Klein M, Raz E, Albani S, Kuis W, et al. TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis. *Ann Rheum Dis* 2012; 71:1706-15; PMID:22562976; <http://dx.doi.org/10.1136/annrheumdis-2011-201131>
- [109] Velasquez LS, Hjeltn BE, Arntzen CJ, Herbst-Kralovetz MM. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. *Clin Vaccine Immunol* 2010; 17:1850-8; PMID:20962211; <http://dx.doi.org/10.1128/CVI.00230-10>
- [110] Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. *Arch Virol* 2010; 155:535-44; PMID:20195654; <http://dx.doi.org/10.1007/s00705-010-0621-4>
- [111] Noda K, Kodama S, Umemoto S, Abe N, Hirano T, Suzuki M. Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx. *Vaccine* 2010; 28:5068-74; PMID:20478344; <http://dx.doi.org/10.1016/j.vaccine.2010.05.005>
- [112] Miyata T, Harakuni T, Tsuboi T, Sattabongkot J, Kohama H, Tachibana M, Matsuzaki G, Torii M, Arakawa T. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit

- induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. *Infect Immun* 2010; 78:3773-82; PMID:20584978; <http://dx.doi.org/10.1128/IAI.00306-10>
- [113] Freytag LC, Clements JD. Mucosal adjuvants. *Vaccine* 2005; 23:1804-13; PMID:15734046; <http://dx.doi.org/10.1016/j.vaccine.2004.11.010>
- [114] Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland. *N Engl J Med* 2004; 350:896-903; PMID:14985487; <http://dx.doi.org/10.1056/NEJMoa030595>
- [115] van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. *J Immunol* 2000; 165:4778-82; PMID:11045998; <http://dx.doi.org/10.4049/jimmunol.165.9.4778>
- [116] Gluck R, Mischler R, Durrer P, Furer E, Lang AB, Herzog C, Cryz SJ, Jr. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing *Escherichia coli* heat-labile toxin as a mucosal adjuvant. *J Infect Dis* 2000; 181:1129-32; PMID:10720540; <http://dx.doi.org/10.1086/315337>
- [117] Kanerva M, Mannonen L, Pliparinen H, Peltomaa M, Vaheri A, Pitkaranta A. Search for herpesviruses in cerebrospinal fluid of facial palsy patients by PCR. *Acta Otolaryngol (Stockh)* 2007; 127:775-9; <http://dx.doi.org/10.1080/00016480601011444>
- [118] Kiura K, Kataoka H, Yasuda M, Inoue N, Shibata K. The diacylated lipopeptide FSL-1 induces TLR2-mediated Th2 responses. *FEMS Immunol Med Microbiol* 2006; 48:44-55; PMID:16965351; <http://dx.doi.org/10.1111/j.1574-695X.2006.00119.x>
- [119] Nyirenda MH, Sanvito L, Darlington PJ, O'Brien K, Zhang GX, Constantinescu CS, Bar-Or A, Gran B. TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function. *J Immunol* 2011; 187:2278-90; PMID:21775683; <http://dx.doi.org/10.4049/jimmunol.1003715>
- [120] Keijzer C, Slutter B, van der Zee R, Jiskoot W, van Eden W, Broere F. PLGA, PLGA-TMC and TMC-TPP Nanoparticles Differentially Modulate the Outcome of Nasal Vaccination by Inducing Tolerance or Enhancing Humoral Immunity. *Plos One* 2011; 6:10
- [121] Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. *Drugs* 2011; 71:1591-622; PMID:21861544; <http://dx.doi.org/10.2165/11206860-000000000-00000>
- [122] Watts PJ, Smith A. Re-formulating drugs and vaccines for intranasal delivery: maximum benefits for minimum risks? *Drug Discov Today* 2011; 16:4-7; PMID:21074635; <http://dx.doi.org/10.1016/j.drudis.2010.11.001>
- [123] Kulkarni PS, Raut SK, Dhere RM. A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac ((R))) in India. *Human vaccines & immunotherapeutics* 2013; 9:122-4; PMID:23442586; <http://dx.doi.org/10.4161/hv.22317>
- [124] Dhere R, Yeolekar L, Kulkarni P, Menon R, Vaidya V, Ganguly M, Tyagi P, Barde P, Jadhav S. A pandemic influenza vaccine in India: from strain to sale within 12 months. *Vaccine* 2011; 29 Suppl 1: A16-21; <http://dx.doi.org/10.1016/j.vaccine.2011.04.119>
- [125] Lycke N. Recent progress in mucosal vaccine development: potential and limitations. *Nature Reviews Immunology* 2012; 12:592-605; PMID:22828912; <http://dx.doi.org/10.1038/nri3251>
- [126] Control CfD. ACIP votes down use of LAIV for 2016-2017 flu season CDC Press Release 2016.
- [127] Rudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, Rekestin AR, Beljaev AL, Bragina VE, Cox N, et al. Efficacy Of Live Attenuated And Inactivated Influenza Vaccines In Schoolchildren And Their Unvaccinated Contacts In Novgorod, Russia. *J Infect Dis* 1993; 168:881-7; PMID:8376833; <http://dx.doi.org/10.1093/infdis/168.4.881>
- [128] Elveback LR, Fox JP, Ackerman E, Langworthy A, Boyd M, Gatewood L. An Influenza Simulation Model For Immunization Studies. *Am J Epidemiol* 1976; 103:152-65; PMID:814808
- [129] Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, Kruger H, Greiner W. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. *Eur J Health Econ* 2015; 16:471-88; PMID:24859492; <http://dx.doi.org/10.1007/s10198-014-0586-4>
- [130] Meeyai A, Praditsithikorn N, Kotirum S, Kulpeng W, Putthasri W, Cooper BS, Teerawattananon Y. Seasonal Influenza Vaccination for Children in Thailand: A Cost-Effectiveness Analysis. *Plos Medicine* 2015; 12:e1001829; PMID:26011712; <http://dx.doi.org/10.1371/journal.pmed.1001829>
- [131] SNBL. Nasal Flu vaccine using μco^{TM} System. 2015.
- [132] Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, Shin P, Siffert J. AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COM-PASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks. *Headache* 2015; 55:621-35; PMID:25941016; <http://dx.doi.org/10.1111/head.12583>
- [133] Cady R. A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine. *Expert Opinion on Drug Delivery* 2015; 12:1565-77; PMID:26119828; <http://dx.doi.org/10.1517/17425247.2015.1060959>
- [134] Tepper SJ. Clinical Implications for Breath-Powered Powder Sumatriptan Intranasal Treatment. *Headache* 2013; 53:1341-9; PMID:23809006; <http://dx.doi.org/10.1111/head.12166>
- [135] Kurve. KURve ViaNase Electronic Nebulizer. Kurve Technology Inc., www.kurvevtech.com. [accessed on August 2016]
- [136] Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnesic Mild Cognitive Impairment A Pilot Clinical Trial. *Arch Neurol* 2012; 69:29-38; PMID:21911655; <http://dx.doi.org/10.1001/archneurol.2011.233>
- [137] Smith A, Perelman M, Hinchcliffe M. Chitosan: A promising safe and immune-enhancing adjuvant for intranasal vaccines. *Human vaccines & immunotherapeutics* 2014; 10:797-807; PMID:24346613; <http://dx.doi.org/10.4161/hv.27449>
- [138] Le Grand R, Dereuddre-Bosquet N, Dispinseri S, Gosse L, Desjardins D, Shen XY, Tolazzi M, Ochsenbauer C, Saidi H, Tomaras G, et al. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. *J Virol* 2016; 90:5315-28; PMID:27009957; <http://dx.doi.org/10.1128/JVI.00230-16>
- [139] Lebre F, Borchard G, Faneca H, Pedrosa de Lima MC, Borges O. Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice. *Mol Pharm* 2016; 13:472-82; PMID:26651533; <http://dx.doi.org/10.1021/acs.molpharmaceut.5b00707>
- [140] Pawar D, Mangal S, Goswami R, Jaganathan KS. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: Effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. *Eur J Pharm Biopharm* 2013; 85:550-9; PMID:23831265; <http://dx.doi.org/10.1016/j.ejpb.2013.06.017>
- [141] Khatri K, Goyal AK, Gupta PN, Mishra N, Mehta A, Vyas SP. Surface modified liposomes for nasal delivery of DNA vaccine. *Vaccine* 2008; 26:2225-33; PMID:18396362; <http://dx.doi.org/10.1016/j.vaccine.2008.02.058>
- [142] Pan L, Zhang Z, Lv J, Zhou P, Hu W, Fang Y, Chen H, Liu X, Shao J, Zhao F, et al. Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles. *Int J Nanomedicine* 2014; 9:5603-18; PMID:25506214; <http://dx.doi.org/10.2147/IJN.S72318>
- [143] Grassini-Delye S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. *Pharmacol Ther* 2012; 134:366-79; PMID:22465159; <http://dx.doi.org/10.1016/j.pharmthera.2012.03.003>